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ABSTRACT 
The increasing frequency of enterococci as a major cause of nosocomial infections and the 
transmission of these organisms amongst hospital patients demands a greater awareness of the 
Enterococcus. Therapy of enterococcal infections is complicated by the pathogens continually 
changing resistance patterns to many broad-spectrum antibiotics. In addition, the ability of 
enterococci to cause serious invasive infections including endocarditis and septicaemia with 
associated high mortality rates; prompted this study which was aimed at identifying the 
biological properties of enterococci isolated from blood cultures of patients admitted at King 
Edward VIII hospital, Durban. 
Enterococci were identified to species level by the API 20 Strep system which identified 68% 
and a conventional biochemical system ofFacklam and Collins which identified 100% of the 
isolates. 
The emergence ofbeta-Iactamase producing enterococci in other countries encouraged the 
testing of all isolates for this enzyme. All were beta-Iactamase negative. 
The reported false susceptibility for aminoglycosides and cephalosporins with blood enriched 
media encouraged the testing of these antibiotics with and without the supplementation of 5% 
lysed blood. 
The results showed that an average false susceptibility of 55 % occurred for gentamicin and 
35% for tobramycin and netilmicin. The cephalosporins affected, cefotaxime and cefuroxime 
showed a false susceptibility of28% and 17% respectively. 
11 
The choice of treatment for serious enterococcal infections is a sYllergistic combination of a 
beta-Iactam antibiotic plus an aminoglycoside for enterococci with intrinsic low-level 
resistance. The development of high-level aminoglycoside resistance, MIC 22000,ug/ml results 
in loss of synergism. This study showed that 26.4 % of enterococcal isolates displayed high-
level aminoglycoside resistance ie. to gentamicin and streptomycin. 
Time-kill study showed reduced killing rate for these organisms for the beta-Iactams and 
glycopeptides with low-level gentamicin resistance. The results confirmed that a cell-wall 
active agent combined with gentamicin can be successfully used for enterococcal therapy if the 
organism has intrinsic low-level resistance to this amino glycoside. 
Pulsed-field gel electrophoresis (PFGE) carried out on a selected number of Enterococcus 
faecalis and Enterococcus faecium with high-level aminoglycoside resistance showed a 
variability in the restriction endonucelase digestion patterns. This suggests independent 
development of high-level gentamicin resistance and not clonal expression. 
The ease and reliability with which enterococcal isolates may be typed using this technique to 
compare different strains represent a significant advance. 
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Enterococci have been called the "nosocomial pathogen of the 1990's". 
They have been given a genus status distinct from the genus Streptococcus, since they 
differ from them by physiological characteristics and by deoxyribonucleic acid (DNA) 
contents. It has been a decade since this nomenclature change was proposed by Schleifer 
and Kilpper-Balz and it is now generally accepted that the genus Enterococcus is valid 
(105). Twelve species have been described namely Ejaecalis, Ejaecium, Edurans, 
Eavium, Ecasseliflavus, Emalodoratus, Egallinarium, Ehirae, Emundtii, 
Eraffinosus, Esolitarius, Epseudoavium (27). 
1 
The genus Enterococcus consists of Gram positive facultatively anaerobic organisms that 
are ovoid in shape. On the Gram stained smear they appear in pairs, singly or in short 
chains. Optimum growth for this organism occurs at a temperature of35-37°e but they 
are able to grow under extreme environmental conditions such as temperatures of 100 e 
and 45°C. Like streptococci, these organisms do not have cytochrome enzymes and are 
catalase negative. Enterococci are differentiated from streptococci by their ability to grow 
in 6.5% salt and at a pH of9.6. Another distinguishing characteristic is their ability to 
survive at 600 e for 30 minutes. 
Enterococci are able to hydrolyse aesculin and grow in the presence of40% bile. They 
also hydrolyse L-pyrrolidonyl-beta-naphthylamide (PYR). 
The genus Enterococcus is classified within Lancefield group D, based on specific 
carbohydrate cell wall antigens. 
This organism is emerging as a problem pathogen within hospitals because of its 
transmission amongst hospital patients, and its problematic antibiotic resistance patterns 
such as, high-level aminoglycoside resistance and multiple resistance tQ a variety of 
antimicrobial agents, including vancomycin. 
2 
The Enterococcus, as the name implies is part of the normal flora of the enteric tract with 
E.faecalis being the most common species. These organisms may be found as colonisers 
from the genitourinary tract, including the endocervical, vaginal and perineal region in 
females, as well as the urethra in both males and females (2). 
Enterococci are important causes of clinical infections particularly bacterial endocarditis, 
urinary tract infections, bacteraemia, neonatal sepsis, soft tissue infections and intra-
abdominal and pelvic infections. 
They have rarely been reported to cause meningitis and pneumonia(6). 
The increased awareness of enterococci as a problem pathogen prompted this study which 
aims at identifying the current biological properties of enterococci in patients admitted to 
King Edward VIII Hospital, Durban. 
107 enterococci, isolated from blood cultures in 1994 at King Edward VIII Hospital, 
Durban were used in this study. 
The enterococci were identified by the Analytical Profile Index (APT) Strep System (Bio 
Merieux) and by conventional biochemical tests and classified according to Lancefield 
grouping using the Streptex Latex Kit (Murex).Electrophoretic analysis of chromosomal 
DNA patterns by pulse-field gel electrophoresis (pFGE) was performed on a selected 
number of isolates. 
Reports of enterococci producing plasmid-mediated beta-Iactamase have further 
decreased the choice of antibiotics for treatment (74). As with many beta-Iactamase 
producing organisms the amount ofbeta-Iactamase enzyme produced appears to be 
inoculum dependent. 
3 
In a low inoculum of enterococci ie. <106 CFU/ml, a small amount of enzyme would be produced, 
thus beta-Iactamase susceptible antibiotics such as ampicillin can overwhelm the enzyme resulting 
in an inhibition of growth around the antibiotic disc. This can result in false susceptible results for 
penicillin, ampicillin, piperacillin and other ureidopenicillins such as azlocillin and mezlocillin (77). 
This problem can be overcome by performing a beta-Iactamase test routinely or ensuring that an 
inoculum of at least 107_108 CFU/ml is used. 
Antimicrobial susceptibility testing was performed (modified "Stokes" method, Kirby-Bauer 
method, minimum inhibitory concentrations and breakpoint method) . Isolates were tested for 
beta-Iactamase production by means of the chromogenic cephalosporin method (Nitrocephin). 
High-level amino glycoside resistance (MIC ~ 2000Ilg/ml) was measured for gentamicin and 
streptomycin. 
Synergism studies were performed using time-kill curves on a selecte<;l number of isolates. 
F or the appropriate treatment of infection, rapid, convenient, reproducible, reliable and 
discriminatory methods for susceptibility testing are relevant aids to the clinician. 
The use of the appropriate media for susceptibility testing of enterococci is important since there 
have been reports of the disc diffusion, minimum inlnbitory concentrations (MIC) and breakpoint 
susceptibility testing methods giving false susceptible results for aminoglycosides and 
cephalosporins when blood enriched media are used (40,98,109). 
This has prompted a comparison of susceptibility test results for the aminoglycosides and 
cephalosporins with and without the addition of blood to the media. Two disc diffusion methods 
were compared ie. modified "Stokes" technique and the Kirby-Bauer method. 
4 
Minimum inhibitory concentrations (MIC) were determined by the agar dilution method and 
micro dilution technique for the glycopeptides so that minimum bactericidal concentrations (1tffiC) 
could be performed for vancomycin and tei~oplanin. This was to determine these antimicrobial 
agents killing effect (ie. bactericidal or bacteriostatic). Breakpoint susceptibility testing was 
performed according to National Committee for Clinical Laboratory Standards (NCCLS 
Document M lOO-S4 Vol.12 No.20) values. 
Presently, the most disturbing development relates to the reports of vancomycin resistance among 
enterococci isolated from patients in France, England and the United States of America with 
MICs ranging from 64 to > 2000,ug/ml (50,97). 
In view of this observation the universal susceptibility to this antibiotic can no longer be presumed 
and one should be on the lookout for vancomycin resistant isolates. 
The choice of treatment for enterococcal endocarditis is a synergistic combination of a beta-
lactam antibiotic plus an aminoglycoside. Enterococci have naturally low-level resistance to 
aminoglycosides with minimum inhibitory concentrations of s; 500,ug/ml. Their cell wall has 
limited permeability to aminoglycosides due to the absence of proton motor force (PMF). The 
synergistic combination of a cell wall antibiotic plus an amino-glycoside, is believed to be caused 
by the disruption of the bacterial cell wall by penicillin, ampicillin or vancomycin. 
This facilitates the penetration and uptake of the amino glycoside into the bacterial cytoplasm to 
thus allow the aminoglycoside to act on the bacterial ribosomes, killing the bacterium (67,44). 
When high-level aminoglycoside resistance occurs, synergism is lost (99) . High-level 
aminoglycoside resistance is defined as occurring when a drug concentration of ~ 2000,ug/ml is 
required for inhibition of the organism. 
The development of high-level aminoglycoside resistance is believed to occur as a result of 
selective pressure from the use of broad spectrum antibiotics and the aminoglycosides (57). By 
acquiring transferable plasmids that encode for various amino glycoside modifying enzymes, 
enterococci can exhibit such a phenomenon (19,60). 
High-level resistance to gentamicin in enterococci is due to the acquisition of aminoglycoside -
modifying enzymes namely 6'-acetyl transferase 2"-phosphotransferase (6'-AAC-2"APH). 3'-
aminoglycoside-phosphotransferase enzyme (3'-APH) is responsible for high-level resistance to 
amikacin. 
Streptomycin high-level resistance is caused by aminoglycoside inactivating enzyme 3"-
adenyltransferase (3"-ANT) (90). 
High-level gentamicin and streptomycin resistance has disseminated among local strains and will 
undoubtedly continue to spread. 
5 
Such resistance is relatively easily detected in the laboratory by high-content discs (120 or 500,ug 
of gentamicin, 300 or 1000,ug of streptomycin), by means of using a plate or broth screen method 
incorporating the appropriate aminoglycoside at a concentration of 500 and/or 2000,uglml. 
More recently, an Etest (AB Biodisk Solva, Sweden) has been developed to predict high-level 
aminoglycoside resistance. 
In this study strains were tested for the detection of high-level resistance to gentamicin, and 
streptomycin, using the plate screen method. 
The range of antimicrobial agents available for treatment in enterococcal infections is limited. 
With the emergence of resistance to ampicillin as well as vancomycin, susceptibility testing gains 
importance. The ability of enterococci to develop resistance to a number of useful antimicrobial 
agents would continue to make this organism a major challenge for the development of new and 
more effective antibiotics. 
6 
Since enterococci have been implicated in hospital acquired infections, typing of isolates is helpful 
in epidemiological studies. Different patients infected with a single strain suggests that inter-
patient transmission has occurred. 
Molecular epidemiology of strains of enterococci were determined by pulsed-field gel 
electrophoresis (pFGE) in E.faecalis and E.faecium with high-level resistance to gentamicin and / 
or streptomycin. 
This method is able to separate large chromosomal DNA fragments by restriction endonucleases 
such as SmaI in agarose gels by using alternately pulsed, perpendicularly oriented electrical fields 
from several directions. This method provides consistent reproducibility and enhances resolution 
of DNA bands, allowing ease and confidence in interpretation of chromosomal bands. 
CHAPTER 2 
REVIEW OF LITERATURE 
2.1 NORMAL DISTmUTION OF ENTEROCOCCI 
7 
The enterococci, as their name implies are part of the normal flora of the enteric tract. Efaecalis 
is the most common isolate, and the concentration increases progressively from the mouth to the 
large bowel (85). The organism is present in the faeces of most normal adults and carrier isolation 
rates of as high as 100 percent have been reported in some studies (8). 
On the other hand, Efaecium has usually been found much less frequently. Given the colonisation 
of enterococci from the large bowel and the ability of these organisms to survive in high 
concentrations of bile it is not surprising that enterococci are involved in biliary infection. In 
addition, these organisms may be isolated in small numbers from the normally colonized part of 
genito-urinary tract, including the endocervical, vaginal and perineal region in females (2) as well 
as the urethra of both males and females (46). 
2.2 CLINICAL INFECTIONS 
Enterococci have been recognised as being potentially pathogenic for humans since 1900. 
Enterococcus faecalis causes disease more frequently than any of the other species, perhaps 
because it is more commonly a part of the normal human flora and is usually present in higher 
concentrations. 
Infections in which enterococci are most frequently involved are: 
2.2.1 Urinary tract infections 
Urinary tract infections are the most common type of clinical disease produced by 
enterococci. This usually presents as uncomplicated cystitis but pyelonephritis and perinephric 
abscesses and prostatitis may be seen occasionally (75,25). 
A large number of enterococcal urinary tract infections are nosocomial and a number of factors 
may contribute to acquisition of enterococcal urinary infection, including urinary catheterization, 
frequent instrumentation, recurrent infections, prior antibiotic therapy that select for resistant 
organisms, debilitated patients and finally transmission of organisms that are resistant to a variety 
of antimicrobial agents (75,72,112). 
Currently, enterococci cause about 10 per cent of all nosocomial infections; this includes 
approximately 15 per cent of urinary tract infections according to The Centres for Disease 
Control National Nosocomial Infection Surveillance Survey (86). These numbers are higher as 
compared to the past. Extensive use of cephalosporins is likely to be responsible for such a 
phenomenon. 
2.2.2 Bacteremia and endocarditis 
8 
Although the Enterococcus is capable of causing infections of anatomically normal valves, in most 
cases patients with underlying valvular heart disease or prosthetic valves are involved (75,94). In 
drug addicts, enterococci are estimated to cause between 5-10 per cent of cases of endocarditis. 
One study reported 11 out of20 cases of endocarditis were caused by enterococci (75,92). 
9 
2.2.3 Intra-abdominal and pelvic infections 
Enterococci are part of the normal intestinal flora and are found in approximately 17 per cent of 
routine vaginal cultures (7). They are frequently found as part of the mixed aerobic and anaerobic 
flora involved in intra-abdominal and pelvic infections (24). 
Enterococci have been reported to cause salpingitis, endometritis with bacteremia, abscess 
formation following caesarian section and bacteremia in obstetric and gynecologic patients 
(75,52,87) . 
Enterococci can cause peritonitis in patients with nephrotic syndrome or cirrhosis and in patients 
receiving chronic peritoneal dialysis (34,53). 
2.2.4 N eonatal sepsis 
Enterococci have been documented to cause neonatal sepsis characterized by fever, lethargy and 
respiratory distress in the presence of bacteremia and/or meningitis (12). 
Neonates with enterococcal sepsis have been reported to have responded well to appropriate 
antimicrobial therapy (7,5). 
2.2.5 Meningitis 
Enterococcal infections of the central nervous system are uncommon but have been described in 
all age groups. The predisposing factors are felt to be underlying long term primary disease, 




Enterococci are part of the normal gut flora of all humans. They are capable of causing infections 
both in and out of the hospital setting. Previously it was thought that most infections due to 
enterococci were endogenously acquired (42) . The emergence of multi-resistant enterococci 
causing severe nosocomial infections has focused attention on risk factors for acquisition and 
spread of these organisms. Recent evidence suggests that most enterococcal infections occurring 
in hospitalized patients or in patients undergoing therapy such as peritoneal or hemodialysis are 
exogenously acquired (42). There is evidence that enterococcal strains spread between patients 
and may even disseminate between institutions (80,81 ,118). Strains of enterococci causing 
nosocomial infections have occasionally been found on the hands of medical personnel and have 
been frequently isolated from environmental sources in hospitals and nursing homes (118,116). 
It appears that resistant organisms from patients or hospital personnel first colonize the 
gastrointestinal tract or occasionally the skin especially the skin folds like the groin before causing 
infections in patients (93). In the United States, currently enterococci rank second or third in 
frequency as the cause of nosocomial infections (102). 
As yet, no data is available for South Africa. Risk factors for acquiring nosocomial enterococcal 
infections include serious underlying disease, prolonged hospitalization, prior surgery, renal 
insufficiency, presence of urinary catheters or bladder instrumentation, stay in an intensive care 
unit (leU) and prior antimicrobial therapy (especially aminoglycosides or cephalosporins). This is 
a major risk factor for acquistion of resistant enterococci (42,116,36,114,15,68). 
Other antimicrobial agents that have been associated with enterococcal nosocomial infections 
include azthreonam, imipenem, ciprofloxacin and vancomycin (36,115,41). 
Studies among paediatric patients show that low birth-weight, premature infants with severe 
underlying conditions, invasive procedure such as intubation, umbilical vessel catheterization, 
gastrointestinal surgery, use of non-umbilical central catheter, days of central line in place and 
bowel resection were identified as significant risk factors for enterococcal sepsis in neonates 
(59,23). 
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Studies done by Zervous et al.(116) have shown that previous antimicrobial treatment particularly 
with aminoglycosides or cephalosporins, perioperative antibiotic prophylaxis, previous surgery, 
longer hospitalization and bladder catheterization are risk factors for high-level gentamicin 
resistance in E. faecalis. 
Axelrod et al. ( 4) reported that hospitalization for longer than 2 weeks and the administration of 
five or more antibiotics to patients were two significant risk factors for colonization or infection 
with Efaecalis displaying high-level gentamicin resistance. 
Hospitalization and prior antibiotic usage including vancomycin were also identified as risk factors 
for the acquisition of ampicillin and vancomycin resistant enterococci. (116,10,54,36). Beside 
longer stay in hospital, female gender, renal dysfunction and preceding imipenem therapy were 
found to be important factors allowing the organism to become endemic. (10,54,36) . 
The majority of outbreaks caused by multi-resistant enterococci have been controlled by strict 
applications of barrier precautions, handwashing and cohorting infected or colonized patients. 
Handwashing with soap and water alone may not be effective for the removal of vancomycin 
resistant Efaecium from heavily contaminated hands (111). 
Alcoholic chlorohexidine which has rapid bactericidal and residual activity was reported to be 
effective. Useful control measures suggested by Handwerger et al.(36) include daily perineal 
washing with chlorohexidine in patients with groin or rectal colonization. 
F or personnel that are colonized with vancomycin resistant enterococci showering with 
chlorohexidine was found to reduce the level of colonization with enterococci. 
In addition, the controlled use of antibiotics has been shown to be effective in the prevention of 
enterococcal nosocomial infections (36) . 
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Since vancomycin usage has been identified as a major risk factor for nosocomial infection with 
vancomycin resistant enterococci (36,96), it is important to use this antibiotic only when there is 
no alternative. 
In recent years, selective decontamination of the digestive tract (SDD) has been proposed as a 
means of reducing nosocomial infections. However SDD in intensive care units lead to emergence 
of resistance in general and selection of resistant enterococci in the respiratory and gastro-
intestinal tract.(21). Studies have shown that SDD does not improve survival among patients 
receiving mechanical ventilation and its routine use in intensive care units cannot be recommended 
(31). 
Careful monitoring and use of prophylatic and therapeutic antibiotics has the potential to change 
the current trends in enterococcal nosocomial infections. 
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2.4 RESISTANCE OF ENTEROCOCCI TO ANTlMICROBIAL AGENTS 
Antimicrobial resistance may be either intrinsic or acquired, The term intrinsic resistance is used 
to indicate resistance which is a natural characteristic of a species and therefore present in most or 
all strains of that species (67). The genes for intrinsic resistance, like other species characteristics 
appear to reside on the chromosome. Acquired resistance results from either a mutation in the 
existing DNA or acquistion of new DNA (75). Table I gives an overview of resistance in 
enterococci. 
Table I Resistance found in enterococci 
INTRINSIC (Naturally occurring ACQUIRED RESISTANCE 
resistance) 
Aminoglycoside (Low-level resistance Aminoglycoside (High-level resistance 
:MIC ~ 500f,l-g1ml) :MIC ~ 2000f,l-g1ml) 
Beta-Iactams,particularly semi-synthetic Chloramphenicol 
penicillinase resistant penicillins and 
cephalosporins (manifested by relatively 
high :MICs) 
Clindamycin (Low-level) Erythromycin and high-level clindamycin 
Fluoroquinolones 
Penicillins via penicillinase 
T etracyc1ine 
Vancomycin 
In addition to the relative high MICs with beta-Iactams (penicillin, ampicillin, imipenen) 
enterococci, typically have very high minimum bactericidal concentrations. 
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(MBCs> 128,ug/ml) and are thus a natural example ofbeta-Iactam tolerant organisms (75). The 
lack of bactericidal activity presumably explains the high failure rate when single drug therapy is 
used to treat endocarditis caused by susceptible enterococci (73). 
In recent years there have been several suggestions that the prevalence of strains of Ejaecium 
with higher levels of intrinsic resistance to penicillin and related beta-Iactams is increasing and 
there have been a number of reports of outbreaks of infection with strains of Efaecium for 
which MICs of penicillin ranged from 32 to 256,ug/ml(13). 
High-level resistance of Ejaecium to penicillin, not due to beta-Iactamase production has been 
increasingly reported.Most evidence suggests that resistance of this species to penicillin is due to 
the low overall affinity of its penicillin binding proteins. In Europe and the USA the prevalence 
rate of this species of enterococci is between 10 and 20 percent (88). 
Resistance to ciprofloxacin has also emerged in isolates causing infection in patients on such 
therapy, presumably due to mutations (115). From 1985 to 1986, ciprofloxacin resistance was 
only 1,4 percent in the USA. 
In 1989 to 1990, ciprofloxacin resistance had increased significantly to 15,2 percent (103). Most 
ciprofloxacin resistance occurred in strains showing high-level gentamicin resistance, 24 percent 
of gentamicin-resistant strains were resistant to ciprofloxacin (l03).Low-level resistance to 
aminoglycosides (MIC 16-256 ,ug/ml) is an inherent trait due to the lack of proton motive force 
mediated transport. 
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Aminoglycoside uptake is markedly increased in the presence of cell wall active agents such as 
penicillin and ampicillin and synergy of killing occurs with the combination of these agents when 
high-level aminoglycoside resistance is not present. 
High-level aminoglycoside resistance is defined as an MIC of ~ 2000,ug/ml; resistance is due to 
the production of aminoglycoside - modifying enzymes. The clinical significance of this 
resistance is that it eliminates synergy with beta-Iactam antibiotics thereby preventing 
bactericidal activity. The genes coding for aminoglycoside modifying enzymes responsible for 
this type of resistance appear to be transferable and are situated on plasmids or transposons. 
High-level resistance to erythromycin in enterococci is plasmid mediated and widely distributed. 
Tetracycline and chloramphenicol high-level resistance has also emerged. 
Transferable high-level resistance to trimethoprimlsulfamethoxazole has been reported, and is 
thought to be due to an altered dehydrofolate reductase of E.faecium strains which are 
intrinsically resistant (88). 
In addition to their resistance and tolerance to beta-Iactams, enterococci have recently acquired 
the ability to directly inactivate penicillin and ampicillin by the production ofbeta-Iactamases. 
The first beta-lactamase producing Enterococcus was described in Houston, Texas in the year 
1983 (82) . Subsequently, beta-Iactamase producing enterococci have been isolated from a 
number of different locations in the United States of America. Fortunately, its spread is limited 
so far. 
The enterococcal beta-Iactamases hydrolyse penicillin, ampicillin, piperacillin and other 
ureidopenicillins which correlates with resistance to these compounds; there is little or no 
inactivation of penicillinase -resistant semisynthetic penicillins, cephalosporins or imipenem 
(78,77) . With few exceptions, beta-Iactamase producing enterococci have also exhibited high-
level resistance to gentamicin (89) . 
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The latter 1980's had seen the development of vancomycin resistant enterococci isolated from 
patients in France, England and the United States of America with MIC ranges from 64-
2000,uglml (50,97) . Recently, such isolates have been reported from Johannesburg as well (43). 
Although the incidence of vancomycin resistance remains low, it threatens an indispensable 
therapeutic alternative in the penicillin - allergic patient or for enterococcal infections, with 
penicillin and ampicillin resistance. Three phenotypes of vancomycin resistance have been 
described for enterococci, Van A, Van B and Van C (76). 
Van A isolates, primarily Ejaecium, are highly resistant to vancomycin (MIC > 1000,uglml) 
and are cross resistant to teicoplanin. Van B, in relation to both E.faecium, and Ejaecalis, are 
moderately resistant to vancomycin (MIC 16-1000,uglml) but remain susceptible to teicoplanin. 
Van C also has low-level resistance and affects vancomycin only. Recent studies with Van A, 
Van B, Van C isolates have shown that the gene for Van A but not Van B is carried on a variety 
of plasmids and is transmissable to other enterococci, streptococci and listeriae (76,20). 
Van A and Van B resistance are both inducable in the presence of antibiotics and induction is 
accompanied by the synthesis of new membrane-associated proteins (76). 
These proteins interfere with vancomycin activity by protecting or modifying the N-acyl-D-
alanyI-D-alanine terminal residues in the cell wall (20). 
17 
Teicoplanin is an agent that is still available for vancomycin resistant isolates of the Van Band 
Van C types, however at least three quarters of vancomycin resistant enterococci are resistant to 
teicoplanin as well (63). 
Glycopeptide resistant enterococci are the cause of currently untreatable nosocomial entercoccal 
infection. The paucity of new antimicrobial agents effective against enterococci suggests that, 
physicians can expect to encounter such infections with growing frequency. 
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2.5 PRESUMPTIVE IDENTIFICATION 
It has been a decade since Schleifer and Kilpper-Balz proposed that enterococci should be given 
a genus status distinct from streptococci, since they differ from streptococci by physiological 
characteristics and DNA contents. It is now generally accepted that the genus Enterococcus is 
valid (104). Twelve species of enterococci have been proposed namely, Ejaecalis, Ejaecium, 
Edurans, Eavium, Ecasseliflavus, Emalodoratus, Egallinarium, Ehirae, Emundtii, 
Eraffinosus, Esolitarius, Epseudoavium (104,17,18,29,45). 
The genus Enterococcus consists of Gram positive aerotolerant organisms that are ovoid in 
shape. On the Gram stained smear they appear in pairs, singly or in short chains. Optimum 
growth of this organism occurs at a temperature of 35°C but they are able to grow under 
extreme environmental conditions such as temperatures of 10° and 45°C. Like streptococci, 
these organisms do not have cytochrome enzymes and are catalase negative. Enterococci are 
able to grow in 6.5% NaCI and at a pH of9.6. They are able to survive 30 minutes at 60°C and 
will grow in the presence of 40% bile. Enterococci hydrolyse aesculin and 
L-pYITolidonyl-~-naphthylamide (PYR). Cell walls of most enterococci contain the 
streptococcal group D antigen. 
Although the above mentioned tests appeared to be sufficient in the past for the presumptive 
identification of enterococci, it has now been recognised that other less commonly encountered 
gram-positive cocci can also give a positive reaction in some of these tests (28). For example, 
some cultures of Lactococcus, Pediococcus, Leuconostoc and Aerococcus species can grow in 
the presence of6.5% NaCI and are bile-esculin positive. Some Lactococcus, Aerococcus as 
well as Leuconostoc species are PYR positive. Certain strains of Pediococcus and Leuconostoc 
species possess the group D antigen. 
The tests used to differentiate the eight different genera of gram-positive, catalase negative, 



















Basic reactions to place the Gram-positive cocci into eight genera 
are as follows (28) 
REACTION (% POSITIVE) 
Entero Strepto- Lacto- Aero- Gemella Pedio- Leuco- Lacto-
coccus coccus coccus coccus (15)* coccus nostoc bacillus 
(200)* (645)* (16)* (42)* (26)* (50)* (42)* 
<1 0 0 0 0 0 100 50 
<1 0 0 0 0 100 100 90 
80 0 0 0 0 95 35 25 
99 10 75 60 0 100 90 50 
100 4 69 100 73 0 0 7 
100 0 56 100 0 35 60 40 
99 35 25 0 0 83 0 60 
85 <1 100 0 0 4 75 100 
* : No. of strains tested. 
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These tests identifY the bacteria as members of the genus .enterococcus. They can be further 
identified to species level using key phenotypic characteristics to form three groups as shown in 
table III (28). 
Table III Key tests for identification of enterococci groups 
REACTION (% POSITIVE) 
SPECIES GROUP MAl'lWTOL SORBITOL SORBOSE ARGll'l1NE 
Eavium 









Ehirae III -(7) -(0) -(0) +(100) 
E.faecalis 
(variant) 
Enterococci may be placed into groups I, II, III (28). 
Once grouped, the unknown organism can usually be identified to the species level, by selected 
tests as described in tables IV, V, VI. Table VII and VIII indicate additional tests used to 
complete the identification of the enterococcal isolate if the initial identification profile obtained 
fails to identity the isolate. 
Table IV Identification of group I Enterococcus species 
SPECIES REACTION (% POSITIVE) 
ARABINOSE RAFFINOSE 
E.avium 
' /_1""\. '\ -(0) --r~'J'J ) 
E raffinosus +(100) +(100) 
Emalodoratus -(0) +(100) 
Epseudoavium -(0) -(0) 
Table V Identification of group IT Enterococcus species 
SPECIES REACTION (% POSITIVE) 
ARABINOSE SORBITOL LACTOSE MOTILITY PIGMENT 
Efaecalis -(0) +(96) +(100) -(0) -(0) 
Esolitarus -(0) +(100) -(0) -(0) -(0) 
Egallinarium +(100) -(0) +(100) +(100) -(0) 
Efaecium +(100) V(29) +(97) -(0) -(0) 
Ecasseliflavus +(100) V(50) +(100) +(100) +(100) 
Emundtii +(100) V(50) +(100) -(0) +(100) 
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Table VI Identification of group ID Enterococcus species 
SPECIES REACTION (% POSITIVE) 
SUCROSE RAFFINOSE PYRUVATE 
E.durans -(0) -(0) -(0) 
E.hirae +(88) +(75) -(0) 




Table VII Further tests used to differentiate Enterococcus species 
REACTION (% POSITIVE) 
STRAIN ACID FORMATION HIPPURATE 
HYDROLYSIS 
Glucose Inulin Melibiose Trehalose 
E.avium 44 0 50 100 0 
E. raffinosus 93 0 100 100 33 
E. malodoratus 0 0 100 100 0 
E.pseudoavium 0 0 0 100 0 
Efaecalis 93 0 4 99 24 
E.solitarus 100 0 25 100 100 
E.gallinarium 0 0 100 100 62 
Efaecium 0 0 81 100 23 
E. casse liflavus 63 75 100 100 0 
E.mundtii 0 0 100 100 0 
E.durans 0 0 75 100 33 
E.hirae 0 0 88 100 13 
Efaecalis 0 0 0 75 100 
(variant) 
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Table VIII Additional tests used to differentiate Enterococcus species 
REACTION (% POSITIVE) 
STRAIN GROWTH TOLERANCE VP GROUPD 
ANTIGEN 
lO DC 0.04% 
TELLURITE 
Eavium 66 0 62 32 
E raffinosus 27 0 66 40 
E malodoratus 100 0 0 100 
Epseudoavium 100 0 0 0 
E.faecalis 99 93 89 91 
E. solitarius 75 0 75 100 
E gallinarium 100 8 62 100 
E.faecium 97 3 89 68 
E casseliflavus 75 0 25 100 
Emundtii 100 50 100 100 
E.durans 100 0 100 75 
Ehirae 100 0 100 63 
E.faecalis 100 0 0 100 
(variant) 
2.6 LANCEFIELD GROUPING 
Grouping of the family Streptococcaceae has been classically done by serotyping using the 
Lancefield classification. The Lancefield system is based on the immunological detection of 
antigens, associated with the cell wall ofthe bacteria. (Groups A,B,C,D,F,G). In the classic 
Lancefield test these antigens are extracted in soluble form and identified by precipitation with 
homologous antisera. 
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Enterococci express the group D antigen. However, group D antigen is not specific for enterococci, 
but can also be demonstrated on most species of Pediococcus, and some Leuconostoc and all 
Streptococcus bovis. Thus biochemical tests are necessary to differentiate group D reactive 
orgamsms. 
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2.7 BETA-LACTAMASE PRODUCING ENTEROCOCCI 
Beta-Iactamase production was first described for S. aureus in the early mid 1940s (74). The first 
published account of a beta-Iactamase producing Enterococcus was in 1983, when it was found that 
a strain of Ejaecalis isolated in Houston, Texas, in 1981 produced beta-Iactamase (82). The next 
report o~ a beta-Iactamase producing enterococci was in 1987 from Philadelphia (39). Since then; a 
large number of such isolates of Ejaecalis have been reported from at least 11 cities in four 
countries (74). 
The resistance to penicillin or ampicillin ofbeta-Iactamase producing strains is not always detected 
by routine disc susceptibility testing because of an inoculum effect (75) . When a low inoculum is 
used ie. ~ 106 CFU/ml for disc diffusion testing, strains appear to be susceptible but at a high 
inoculum ie. 101-108CFU/ml strains appear resistant (MIC> 500j.lglml) (78) . An inoculum effect is 
due to the fact that low numbers of cells do not produce sufficient beta-Iactamase to inactivate the 
drug in the test system. The enterococcal beta-Iactamase hydrolyzes penicillin, ampicillin, 
piperacillin and other ureidopenicillins (azlocillin, mezlocillin) (78,77). There is little or no 
inactivation of penicillinase resistant semi-synthetic penicillins, cephalosporins or impenem. 
In most staphylococci, the amount ofbeta-Iactamase production increases on exposure to penicillin. 
To date, beta-Iactamase production in enterococci is constitutive and remains unchanged on 
exposure (121). However, even though enzyme production is constitutive, the Enterococcus 
produces much less enzyme than a Staphylococcus on exposure. 
Evidence supporting the hypothesis that the capability ofbeta-Iactamase production has been 
recently acquired by enterococci is that it is almost always associated with high-level resistance to 
gentamicin (74). 
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Another important concern is that the transferable penicillinase activity may disseminate into other 
streptococci species such as group-A streptococci or Streptococcus pneumoniae for which penicillin 
is presently the most effective therapy. This is of great concern since it is well known that some R 
plasmids can transfer between species of the streptococcal family and even to and from 
Staphylococcus aureus (16,26). 
Hence, there is a possibility of the occurrence ofbeta-Iactamase production in other species of 
streptococci in the future. 
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2.8 ANTIMICROBIAL SUSCEPTffiILITY TESTING 
In vitro tests of antimicrobial activity has come a long way and it has been said that it is as old as 
penicillin itself These tests have undergone man2y changes resulting in a variety of techniques. This 
was inevitable in view of the emergence of new pathogens, the frequent introduction of new 
antibiotics for the treatment of infections and the rapid development of new automated equipment 
for susceptibility testing. 
Many different methods are currently in use, with standardization being achieved by the use of 
control bacterial organisms. In the end, the correct result should predict the response of the patients 
treated with the antimicrobial agents. However, there are many confounding factors that determine 
the relationship between in-vitro susceptibility and clinical response. The goal of susceptibility 
testing in clinical laboratories was defined by a working party of the British Society for . 
Antimicrobial Chemotherapy as follows : 11 to assist the clinician in his choice of an appropriate 
therapeutic or prophylactic antibiotic for individuals or groups of patients or to help the clinician to 
account for failures of response to empirically selected agents" (I 1 ). 
In addition to these clinical objectives; antimicrobial susceptibility testing in clinical laboratories may 
also be used to provide information on epidemiology and mechanisms of antimicrobial resistance. 
The laboratory provides information that designates organisms as susceptible, intermediate 
(moderately susceptible) or resistant. Susceptible indicates that the infection is likely to respond to 
standard doses of the antimicrobial agent, while resistant implies that the infection is unlikely to 
respond. Infection with an organism designated as intermediate or moderately susceptible mayor 
may not respond to standard doses (which might still be used if the result offailure is of lesser 
clinical significance) but would more probably respond if the drug is concentrated at the site of 
infection or if its dosage is increased (11). 
Antimicrobial susceptibility testing of bacteria may be determined using a number of different 
methods. These include disc diffusion methods (Kirby-Bauer, "Stokes" or Comparative), dilution 
methods (broth or agar), breakpoint method and the Etest. 
In a diagnostic laboratory, a convenient method of performing antibiotic susceptibility tests is 
required and in one form or another, a disc-diffusion method is most commonly used. 
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A solid culture medium is evenly inoculated with the organism to be tested and blotting paper discs 
containing the antibiotics are put on the surface. 
During incubation at 35-37°C for 18-24 hours antibiotic diffuses radially from the disc into the 
medium. Interpretation of the susceptibility of the test organisms depends on the type of disc 
diffusion techniques used. In the Stokes method, the test results are compared to the National 
Collection Type Culture (NCTC) control organism and by comparing the test zone diameter to the 
control organism, the test may be interpreted as susceptible intermediate or resistant. In the Kirby-
Bauer method, the test zone diameter is compared to the National Committee for Clinical 
Laboratory Standards (NCCLS) zone diameter interpretive standards and according to the standard 
zone diameters the tests may be interpreted as susceptible, moderately susceptible or resistant. 
To quantitatively measure the in vitro activity of an antimicrobial agent against a bacterial culture a 
broth or agar dilution technique may be used. Basically a series of two fold dilutions of the 
antibiotic is prepared in an agar or broth medium. 
The tubes or plates are then inoculated with a suitably standardized suspension of the test organism. 
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After overnight incubation at 35-37°C for 18-24 hours, the tests are examined and the minimum 
inhibition concentrations (MIC) is determined. MIC is interpreted as the lowest concentration of 
antibiotic that inhibits bacterial growth. A known control organism (American Type Culture Control 
- ATCC) or National Collection Type Culture (NCTC) is included with each batch of tests. 
The breakpoint method as used in diagnostic laboratories may be regarded as an abbreviated form 
of MIC determination using one or two chosen concentrations of the antibiotics to be tested. The 
range of antimicrobials selected for inclusion within a breakpoint testing scheme is related to the 
species of organisms tested and the clinical site ifinfection from which they are isolated. The 
concentrations are selected in order to inhibit susceptible bacteria and allow resistant strains to 
grow. Test and control organisms are spot inoculated on the surface of an agar plate by use of a 
replicating apparatus. Inoculated plates are incubated at 35-37°C for a period of 18-24 hours and 
observed for the presence or absence of bacterial growth. 
If one yoncentration is used, results can be interpreted as susceptible if there is no growth, or 
resistant if growth is observed. If two concentrations are used, results are interpreted as susceptible 
if there is no growth on both concentrations, intermediate or moderately susceptible if there is 
growth on the lower concentration only. Results are interpreted as resistant when both 
concentrations show growth. 
More recently susceptibility testing may also be performed using the Etest [AB Biodisks solva, 
Sweden]. Briefly, the Etest consists of a impervious strip impregnated with a continuous 
antimicrobial gradient. It is a new in-vitro susceptibility testing method used for the quantitative 
determination of susceptibility to antimicrobial agents. 
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The strip is applied to the surface of an agar plate that has been inoculated evenly with a 
standardised inoculum of the test organism. This technique involves the diffusion of a continuous 
antimicrobial gradient from a thin plastic strip, producing an organism inhibition eclipse at which the 
minimum inhibitory concentration (MIC) is read, after incubation at 35-37°C for 18-24 hours. The 
MIC is recorded at the intersection of growth on the MIC scale of the strip. 
The selection of antibiotics for testing and reporting should be done in a manner that encourages the 
use of the most effective and least expensive drug whenever possible. 
The general drug selection is based on the type of organism been tested, the body site from which 
the organism was isolated, and the drugs available for use in a particular institution (100). 
In the case of enterococci routine determination of susceptibility to penicillin, ampicillin, 
vancomycin and high-levels of gentamicin and / or streptomycin should be done. Ampicillin along 
with a test for beta-lactamase production can be used to detect resistance to other beta-lactam 
antibiotics for enterococci. 
The activity of antibiotics is dependant upon inherent characteristics of the organisms and the drugs 
and is influenced by the enviromnent (media or tube) in which they interact. 
Although routine testing of aminoglycosides is generally not recommended for enterococci, some 
laboratories do include testing of aminoglycoside antibiotics routinely, others may test upon request 
or in selected clinical situations where an aminoglycoside plus a beta-Iactam antibiotic may be used 
for treatment. 
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It has been reported that sheep blood enriched Mueller-Hinton agar frequently gave enlarged zone 
sizes that falsely indicated susceptibility. 
For tobramycin and gentamicin, 72% and 70% respectively of isolates changed from resistance to 
susceptible when 5% sheep blood was used in the media (40) as compared to the same media 
without blood. 
There was less of a problem with amikacin and kanamycin, as false susceptibility only occurred with 
4 and 2% of the isolates respectively (40) for disc diffusion susceptibility testing. 
In comparison, agar dilution MICs demonstrated uniform resistance with or without the presence of 
blood; amikacin and kanamycin showed a false susceptibility rate of 4 - 6 % with sheep blood agar 
plates (40). 
False susceptibility to aminoglycosides was shown to be caused by heme in concentrations as low as 
0.03/Lg/ml (40). It has been postulated that the heme effect is related to a catalytic cleavage of 
intracellular H20 2 which results in lipid peroxidation (40). 
In an attempt to find other organisms demonstrating false susceptibility to aminoglycosides, Jenkins 
et al. tested 14 non enterococcal isolates by disc diffusion for susceptibility to gentamicin, 
tobramycin, amikacin, and kanamycin to compare media with and without the addition of 5% sheep 
blood. 
The isolates tested included the following : Streptococcus pyogenes, Streptococcus agalactiae, 
Staphylococcus epidermidis, Staphylococcus aureus, Streptococcus equinus and Streptococcus 
bovis, Escherichia coli, Klebsiella pneumonia, Pseudomonas aeroginosa, Providencia stuartii, 
Morganella morgani, Salmonella typhi, Citrobacter freundii and Enterobacter cloacae (40). 
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None of these organisms demonstrated false susceptibility with the aminoglycosides tested. 
Similar effects have been reported for enterococci when tested against second and third generation 
cephalosporins (98,109). 
Disc diffusion results obtained with the addition of blood showed discrepancies of 4% for 
cephalothin, cefamandole and cefoperazone . 
In contrast, there was a much greater discrepancy for cefotaxime [18%] and for cefuroxime, 
ceftizoxime and cefinenoxime [15%] (109). 
Such variations was also observed when different brands of media were used. 
Since this phenomenon has not been observed with other bacterial species, it seems likely that 
intrinsic characteristics of enterococci are contributing factors to the mechanisms involved. 
Sahm et al. (98), have postulated that the reason for false susceptibility to second and third 
generation cephalosporins in enterococcal isolates may be due to interactions between medium 
components and the heterocyclic ring at the 7 -acyl position. This influences their affinity for 
penicillin-binding proteins. This is supported by the fact that this structure is not present in those 
cephalosporins that were not affected. 
2.9 HIGH-LEVEL AMINOGLYCOSIDE RESISTANCE 
High-level aminoglycoside resistance is defined as occurring when a drug concentration of 
::>:2000,ug/ml is required for inhibition ofthe organism (68,14). 
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The development of high-level resistance is believed to occur as a result of selective pressure from 
the use of aminoglycosides and broad spectrum antibiotics (57). 
The genetic determinants encoding the aminoglycoside-modifying enzymes responsible for high-
level resistance were found to be plasmid-mediated. The importance of these observations is that 
high-level amino glycoside resistance confers resistance to bactericidal synergism between the 
aminoglycoside and the cell wall active antibiotics (62). 
Ubukata et al. (110) isolated a bi-functional resistance enzyme from s'aureus that possess both 6'-
acetyltransferase and 2"-phosphotransferase activities. This bi-functional enzyme is also found in 
strains of enterococci. 
Data from Ferreti et al. (30) suggest that the gene specifying this enzyme is plasmid conferred and 
arose as a result of gene function. 
The enzymatic modification catalyzed by these enzymes make the organisms resistant to all 
aminoglycosides (viz. gentamicin, kanamycin, tobramycin,amikacin and streptomycin). 
The aminoglycoside-modifying enzymes are located on the following genetic elements (90) as seen 
in the table below. 
Table IX Activity of aminoglycoside-inactivating enzymes 
AMINOGL YCOSIDE 





AAC6' ± ± 
AAC 3-1 + 
AAC 3-2 + 
ANT 2" + 
AAD3" + 
APH 2" -AAC 6' + 
APH3'-5" + 
ANT 3'-APH 5" + 
AAC 6'-APH 2" + + + 
+ : Inactivation 
± : Aminoglycoside is poor substrate , poor inactivation. 
APH : describes a phosphorylating enzyme 
ANT : describes an adenylating enzyme 





















The number following relates to the carbon atom of the molecule carrying the side chain which is 
attacked by the enzyme. 
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In some cases there is more than one enzyme of the same class which can react at a single site; these 
are further designated -1, -2, etc. 
High-level aminoglycoside resistance is relatively easily detected in the laboratory. This involves the 
supplementation of an agar or broth medium with a particular amino glycoside to a final 
concentration of 500 and/or 2000,ug/ml and the inoculation of the enterococci onto the agar surface 
or broth as described by Moellering et al (68). The inoculum of the organisms adjusted to match a 
0.5 McFarland Standard (approximately 108 CFU/ml) and further diluted to achieve a final inoculum 
of approximately 104_105 CFU/ml. Inoculated plates incubated at 35-37°C and observed for the 
presence or absence of growth after 24 and 48 hours. Any growth on the agar surface or any 
turbidity in the broth method is interpreted as resistance. 
In 1992, Leclercq et al. (51), described an agar disc diffusion method involving the surface 
inoculation of a susceptibility test agar medium such as Mueller-Hinton agar with enterococci onto 
which high content aminoglycoside discs are placed. 
The high content disc concentrations are as follows: gentamicin 500,ug, streptomycin 1000,ug, 
kanamycin IOOOflg. It has been established that kanamycin more accurately predicts high-level 
amikacin resistance than does amikacin (14,62). 





CFU/ml. The surface of the medium is inoculated so that an even distribution of the 
organism is obtained. 
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This has to be done within 15 minutes of its preparation to avoid changes in the inoculum density. 
High-level aminoglycoside discs are applied to the dried inoculated plates using a sterile needle or 
forceps, ensuring even contact of the discs to the medium. Plates are incubated at 37°C for 18 hours 
and the diameter of any zones of inhibition produced around the discs is measured. The zone size 
break points for the detection of high-level aminoglycoside resistance are shown in table X. 
Table X Interpretation of high-level aminoglycoside resistance using 
high-level discs 
INHIBITION ZONE DIAMETER(mm) 
AMINOGL YCOSIDE DISC CONTENTCug) High-level Low-level 
RESISTANCE RESISTANCE 
Gentamicin 500 < 11 :? 17 
Kanamycin 1000 < 10 :? 14 
Streptomycin 1000 < 12 :? 14 
Lower concentration of aminoglycoside discs have also been used: 120,ug of gentamicin, 300,ug of 
streptomycin and 300,ug of kanamycin. Zone diameters of :? 10mm indicates the presence of 
synergy. 
In 1992, it had been established that the Etest may be used to predict high-level resistance to 
aminoglycoside among enterococci (101) . Gentamicin, and streptomycin Etest MIC range from 
0.06 to 1024,ug/ml and 0.125 to 2048,ug/ml . A value of greater than 1000,ug/ml for each of these 
drugs indicates high-level resistance. 
1 II 
III IV 
Fig. 1 Diagrams showing synergistic action with an aminoglycoside 
and penicillin (65) 
I - Enterococcal cell \valls are impermeable to aminoglycosides 
II - The disruption of bacterial cell walls by a penicillin 
III - Allows the aminoglycoside to penetrate, bind to ribosome 
IV - And kill the EnterococclIs 
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2.10 THE STUDY OF SYNERGISM 
Tests for synergism include killing curves, disc diffusion synergism tests and checkerboard 
titrations. 
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Killing curves have been widely applied to the evaluation and comparison of combinations of drugs. 
Usually, only one concentration of each antibiotic is tested, compatible with blood levels during 
therapy. This method provides a dynamic picture of antimicrobial action and interaction over time. 
At periodic intervals, ie. 0, 4 and 24 hours of incubation, colony counts are performed and plotted 
on semilog graph paper with the survivor colony count on the ordinate (y-axis) in logarithmic scale 
and the time interval on the abscissa (x-axis) in the arithmetic scale. Performed with various 
organisms against one drug or with several drugs against the same organism, such rate 
determination then allows one to compare the rates of decline in the in vitro survivor count and thus 
to find the most rapidly bactericidal agent. 
In synergy studies the effect of combinations of drugs is measured. Synergism is defined as a ~ 100 
fold increase in killing at 24 hours with the combination, in comparison with the most active single 
drug. 
Antagonism is defined as ~ 100 fold decrease in killing with the combination of antibiotics, in 
comparison with the most active single antibiotic. Additive effect or indifference on the other hand 
is described as no increase in killing with the drug combination, in comparison with the most active 
single drug. 
The disc diffusion method can also be used to assess interactions of antimicrobials. This technique 
uses a standardized inoculum of approximately 108CFU/ml on a suitable agar plate. 
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To assess possible interactions between two drugs discs containing the different drugs are placed on 
the plate that has been inoculated with the test organism. 
The distance by which the discs are separated is generally equal to or slightly less than the sum of 
the radii of their zones of inhibition when examined alone. After overnight incubations, 16-18 hours 
at 35 to 37°C the plates are examined. 
The pattern observed with additive or indifferent combinations is that of two independent circles. 
With synergistic combinations, enhancement or bridging is observed at or near the junction of the 
two zones of inhibition. With the antagonistic combinations, truncation is observed near the junction 
of the two zones of inhibition as seen in fig . 2. 
I ADDITIVE (Indifferent) II SYNERGISTIC 
III ANTAGONISTIC IV SYNERGISTIC 
Fig. 2 Assessment of antimicrobial combinations with the disc diffusion 
technique(55) 
A&B 
II & IV 
III 
Discs containing antibiotics placed on Mueller-Hinton agar plates 
inoculated with a' bacterial isolate 
Indicates an additive or autonomous result. 
Indicates synergism 
Indicates antagonism 
(Shading: Indicates bacterial gro\\1h, 
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Fig.3 Time-kill curve showing bactericidal effect and antimicrobial synergy (55) 
C Control (No Antibiotic) 
A Antibiotic A 
.B. : Antibiotic B 
A + B : Both Antibiotics 
PANEL I : Additive, Indifferent or 
Autonomous effect 
PANEL 11 : Synergistic effect 
PANEL III : Antagonism is illustrated 
43 
The combined antibacterial action of two drugs can be precisely determined by performing a 
checkerboard titration. In this method a suitable range of dilution of both drugs is added to broth 
(or agar) so that every concentration of each drug is present alone and in every possible 
combination with the other. The range of concentrations should include that which is inhibitory 
for each drug acting alone. The test is inoculated with a standard inoculum of approximately 106 
CFU/ml. 
The test is incubated at 35 - 37°C for 16-24 hours and if the control tube shows good growth, 
the presence or absence of growth is recorded. 
Synergy is only considered significant if the concentration inhibiting growth in the combination is 
at least 4-fold lower than that of one drug acting alone. 
Cidal synergy occurs only when both drugs tested singly are bactericidal. Such synergy is for ego 
observed with the beta-Iactam aminoglycoside combinations. If in such combinations the beta-
lactam is present in a bactericidal concentration, the concentration of aminoglycoside needed to 
give cidal effect with the combination can be well below the MIC. 














G = Growth in tube/ agar. 
- =No growth 
8 4 2 1 
- - - -
- - - -
- - - -
- - - -
- - - -
- - - -
- - - -
- - - G 
G G G -
The bottom horizontal row contains only streptomycin. 
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G G G 
G G G 
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The remainder of the square will have every possible combination of both drugs, indicated in the 
top horizontal and left hand vertical row. 
The tube in the top right-hand corner is the drug-free control marked N . 
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Cidal antagonism is seen when the cidal action of one antibiotic (eg. penicillin) is eliminated by the 
presence of the second drug ( ego tetracycline). 
Although resistance to antimicrobials may be the result of drug-inactivating enzymes (9,22), or an 
insensitive target site [ego a ribosome resistance to aminoglycoside (120,119)], it may also be due to 
a permeability barrier. In these situations, a drug could become active, if another agent altered the 
permeability of the bacterial cell in order to permit its entry. 
It has been postulated that beta-Iactams may enhance the entry of aminoglycosides in this manner in 
a number of bacterial species (55). 
Work on enterococci (Ejaecalis) has shown that the uptake of14C-labelled streptomycin is 
significantly increased in the presence of penicillin (69). Furthermore, this effect is not specific for 
penicillin only, it is also seen with other agents acting on the cell wall such as ampicillin and 
vancomycin, all of which presumably act similarly to permit increased entry of aminoglycoside (69). 
In Ejaecalis, it has been stated that sequential exposure to ampicillin, followed by an 
aminoglycoside (amikacin) results in a greater bactericidal effect than when the drugs are applied in 
the reverse order providing support for the primary effect on the cell wall in the initiation of 
bactericidal synergism (56). 
In the case of enterococci, the first observation of penicillin, streptomycin synergism was probably 
made in 1947 (37). 
Subsequently, many other investigators have demonstrated a synergistic effect of penicillin with 
various aminoglycosides against enterococci (38,47,68,70,71). 
It gradually became apparent that not all enterococci were synergistically killed by these 
combinations. The explanation for this discrepant behaviour among clinical isolates of enterococci 
was not clear until 1970, when two groups of investigators pointed out that enterococcal isolates 
with high-level streptomycin resistance (MIC ~ 2000.uglml) were resistant to the penicillin, 
streptomycin combinations (68,107). 
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Subsequent work showed that penicillin enhances the uptake of radiolabelled p4C] streptomycin in 
strains with and without high-level streptomycin resistance (69). 
Therefore, it seemed unlikely that the resistance to synergism observed in strains with high-level 
streptomycin resistance was due to maintaining a permeability barrier. 
However streptomycin failed to inhibit the incorporation of radiolabelled phenylalanine into 
trichloroacetic acid - precipitable material and also failed to cause misreading (120,119). This 
affinity of the ribosomal target site suggests that the resistance is the result of decreased 
amino glycoside concentration. 
Additional studies showed that strains with high-level streptomycin and kanamycin resistance 
contained a 45 megadalton (MDa) plasmid that was transferable by conjugation. Transfer of the 
plasmid resulted in high-level resistance and resistance to synergy in the recipient strain (49). 
Thus, it seems clear that at least in some clinical isolates of enterococci a conjugative plasmid is 
responsible for the observed resistance to penicillin plus aminoglycoside synergism. This made an 
altered ribosome as the mechanism of resistance unlikely. 
Subsequently, aminoglycoside - inactivating enzymes were found, which explain the observed 
resistance to synergism. In resistant strains phosphotransferase inactivates amikacin and kanamycin 
by phosphorylating the 3'-hydroxyl group, and an adenyltransferase inactivates streptomycin (48) . 
47 
Fig. 4 shows the different mechanisms of resistance for beta-Iactam aminoglycoside synergy. 
The mechanism of high-level aminoglycoside resistance in clinical isolates of E.faecalis studied to 
date is usually plasmid-mediated synthesis of aminoglycoside - inactivating enzymes, but ribosomal 
resistance and other mechanisms play a role in some strains, especially those with high-level 
streptomycin resistance alone. In vivo resistance to synergism is also observed in combinations that 
are synergistic in vitro. 
Mechanisms of such resistance are multiple. The most important factors appear to be protein 
binding of one or both drugs and the relationship of the MIC of the p-Iactam antibiotic to achievable 
serum and tissue levels (55). The recent demonstration of transferable beta-Iactamase production 
raises the possibility that this trait could spread widely among enterococci and this would then 
obviate the utility of penicillin plus aminoglycoside synergism. 
Penicillin Plus: 
SiREPTOMYCIN ~~ -CJ 
[ANT in ~Foecolis /1 7/~~ANT 
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Fig. 4 Mechanisms of resistance to penicillin + aminogJycoside synergism against 
enterococci (55) 
Of these resistance mechanisms, the most prevalent are enzymatic inactivation. Ribosomal 
resistance to streptomycin also occurs. Enzymatic resistance is also plasmid-mediated. 
although the AAC(6') in Efaecium appears to be chromosomal (ANT = adenyltransferase, 










2.11 TYPING OF ENTEROCOCCI USING PULSED-FIELD GEL ELECTROPHORESIS 
The principle theoretical advantage of these new electrophoretic approaches over biotyping of 
isolates is that since these methods samples the chromosome, it is independent of phenotypic 
changes (35). Furthermore, unlike plasmid analysis, it is the stable part of the genome which is 
sampled. The approach is useful in practice because it is highly discriminatory, stable and may be 
used to type different types of bacteria (35) . 
The epidemiological analyses of nosocomial pathogens is a problem of long-standing interest. 
Epidemiological assessment of enterococci has been limited by the lack of a convenient, 
reproducible and discriminatory method for comparing isolates. Recently, different methods for 
genotyping have been used for the comparison of such isolates (ie. molecular epidemiology). For 
example, restriction fragment chromosomal patterns (RFCP - analysed by agarose gel 
electrophoresis) have been utilized in the epidemiologic analysis of a variety of nosocomial 
pathogens (32). However, restriction enzymes used generate a large number of DNA fragments 
thus making it difficult to accurately compare different isolates (32). 
Restriction endonucelases have been identified that rarely cut the bacterial chromosome 
ego < 20 restriction sites (32). However, most of the resulting DNA fragments are too large to be 
resolved by conventional gel electrophoresis. 
Until recently, large fragments were not possible to separate. A number of "alternative" 
electrophoretic methods such as contour clamped homogeneous electric (CHEF), pulsed-field gel 
electrophoresis (pFGE) and field-inversion gel electrophoresis. (FIGE) have been shown to be 
capable of separating the mega-base sized chromosomal DNA fragments produced by rare cutting 
enzymes (32). 
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These methods provide the advantage that fragments of DNA over a much wider size range (ie. 10 
Kb- 1.5Mb) can be resolved on a single gel, thus generating interpretable patterns. These techniques 
yield restriction endonuc1eases digestion patterns which consist of relatively few, generally well 
separated fragmeJ;lt bands and which are much less ambiguous than the patterns generated by 
conventional electrophoresis (1) . 
Conventional agarose gel electrophoresis utilizes unidirectional electric fields to separate DNA 
molecules. Their movement is forced through an agarose matrix as they are attracted toward the 
positive electrophoretic charge. Under these conditions DNA molecules < 40Kb in size migrate 
through the agarose gel depending on their size. 
DNA molecules with a molecular weight of> 40Kb display aberrant migration through the agarose 
matrix which is possibly due to a longitudinal orientation of the molecules. This causes them to 
migrate through the gel in a manner that is unrelated to size (32). 
In standard gel electrophoresis the electric field is applied constantly in one direction as shown in 
figs . 5 and 6. Alternative electrophoretic methods such as CHEF, PFGE, and FIGE are able to 
separate large DNA fragments by continually changing the direction of the electric field which is 
applied alternatively in two directions (ie. the location of the positive charge). The time spent in 
each direction is called the pulse time. If the pulse time is too long the DNA molecule will 
effectively reorient itself rapidly to the new field and move by ordinary electrophoresis; no size 
fractionation will occur. At intermediate pulse time (ie. about 30s) molecules spend most of their 
time reorienting and as a result effective fractionation occurs. If the pulse time is too short the 
molecule will not have time to reorient at all, thus no size fractionation will occur. 
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By varying both the direction and the duration of the electric field, these alternative electrophoretic 
methods force the DNA molecules to continually reorient in the agarose matrix. 
The overall result is that mega-base-sized DNA fragments move in the desired direction and are 
electrophoretically separated in the agarose gel (32,107). 
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NORMAL GEL (A) 
DNA 
PULSED-FIELD GEL CB) 
Fig. 5 Separation of DNA by ordinary and pulsed-field gel electrophoresis 
CA) DNA travelling in a matix during standard electrophoresis is oriented parallel to the field 
and is sieved through the matrix. 
CB) DNA travelling in the alternating fields used during pulsed -field gel electrophoresis is 
forced to spend most of its time reorienting itself perpendicular to its long axis. 
, ., , 
\, !!'! 1_-, , 
fJ \, l ., 
~ \, .. ~ , 
DNA molecules Molecules Molecules 
completely spend most only seen 
reorient themselves of their time along the 
along their long axis trying to average 
and no separation reorient. electric field. 
occurs. 
Fig. 6 Separation of DNA molecules by pulsed-field gel electrophoresis (PFGE) 
depends on the pulse time (106) 
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From the three alternative electrophoretic methods described, the most commonly used 
technique for the separation of chromosomal DNA in enterococci is pulsed-field gel electrophoresis 
(79,1 ,80,35). 
Pulsed-field gel electrophoresis (PFGE) involves the embedding of the organisms in agarose, lysing 
the organisms in situ and digesting the chromosomal DNA with restriction endonucleases that 
cleave infrequently such as Sma I.. Sma I was chosen because enterococci have a low guanine plus 
cytosine (G+C) content and thus have relatively few Sma I recognition sites (79). Slices of agarose 
containing the chromosomal DNA fragments are inserted into the walls of an agarose gel. The 
restriction fragments are resolved into a pattern of discrete bands in the gel by an apparatus that 
switches the direction of current according to a predetermined pattern. The DNA restriction 
patterns of the isolates are then compared with one another to determine how similar or different 
they are. 
Isolate A B c 
@ 
I 
Cells grown overnight. 
Each culture embedded in an agarose plug to prevent shearing of DNA. 
Cells lysed in situ and treated to remove inhibitors. 
DNA cut with an infrequently cutting restriction enzyme. 
DNA recognition site: (example) 
. ~ 5' GGCCN NNN NGGCC 3' 
~ CCGGN NNN NCCGG 
1 
I , 
Agarose plugs placed in the sample wells of a gel. 
Pulsed-field electrophoresis (alternating electrical pulses and direction) used 
to separate the large DNA fragments 
A B c 
Fig. 7 Steps involved in performing pulsed-field gel electrophoresis [PFGE] (64) 
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The first report of typing of enterococci by a chromosomal DNA based typing method ie. by pulsed-
field gel electrophoresis was by Murray et al. in 1990 (79). 
Their study compared chromosomal restriction endonuclease digestion patterns of27 isolates of 
Efaecalis from 3 different locations ie. Chile, Texas and Thailand by using pulsed-field gel 
electrophoresis. Most isolates tested gave unique restriction patterns. However, one pattern was 
observed for 5 of 14 isolates from Thailand and patterns were also shared by more than one isolate 
in Chile and Texas. 
In a study by Abraham et aI., pulsed-field gel electrophoresis was used to compare 34 isolates of 
Efaecium from 6 different geographic locations. Their results revealed quite heterogeneous 
patterns. 27 ofthe 34 isolates were differentiated from each other, as defined by one or more 
mismatched fragment bands. Five patterns were shared by 2 or more isolates, and each set of 
isolates with a shared pattern originated in the same medical centre, suggesting a common 
epidemiologic background (1) . 
Pulsed-field gel electrophoresis was used to compare 14 beta-Iactamase producing Efaecalis 
isolated from hospitalized patients in 7 states and 3 continents, in a study by Murray et al.(80). 
The restriction endonuclease digestion patterns of isolates from Connecticut, Massachusetts, 
Lebanon and Argentina were all markedly diflerent, indicating these were different strains. 
However, isolates from Delaware, Texas, Pennsylvania, Florida and Virginia were similar, indicating 
that these isolates were derivatives of a single strain. The spread ofbeta-Iactamase producing 
enterococci within the hospital setting was also demonstrated. 
In comparing alternative electrophoretic methods, it should be noted that chromosomal 
restriction fragments do tend to appear somewhat more diffuse with field-inversion gel 
electrophoresis (FIG E) than with the contour clamped homogeneous electric field (CHEF) or 
pulsed-field gel electrophoresis (pFGE). 
In addition CHEF and PFGE is capable of resolving larger DNA molecules than is FIGE. FIGE is 
potentially faster than the other 2 methods and is less expensive since it utilizes a conventional 
agarose gel electrophoresis apparatus (32). 
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The major goal of strain typing studies is to provide laboratory evidence that epidemiologically 
related isolates collected during an outbreak of disease are also genetically related and thus 
represent the same strain. This information is helpful for understanding and controlling the spread of 
disease in both hospitals and communities. 
Pulsed-field gel electrophoresis demonstrates great promise as an epidemiological and 
investigational tool since it is not difficult to perform and is reproducible. The utilization of this 
technique, should add a new dimension to our knowledge of the epiderhiology of antibiotic 
resistance in enterococci. 
CHAPTER 3 
MATERIALS AND METHODS 
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107 enterococci, isolated :from blood cultures in 1994 at King Edward VIII Hospital, Durban were 
identified by the API 20 Strep System (Bio Merieux) which was compared to conventional 
biochemical tests. All the isolates were classified according to Lancefield grouping and tested for 
the production ofbeta-Iactamase. 
Antimicrobial susceptibility testing was performed, comparing two disc diffusion methods ie. 
modifi~d "Stokes" and the Kirby-Bauer method. 
Breakpoint susceptibility testing and minimum inhibitory concentration (MIC) were also performed 
on all of the 107 enterococcal isolates. 
High-level amino glycoside resistance was measured for gentamicin and streptomycin on all the 
isolates. 
Synergism studies were performed using time-kill curves on a selected number of isolates. 
Electrophoretic analysis of chromosomal DNA patterns by pulse-field gel electrophoresis (pFGE) 
was performed on a selected number of Efaecalis and Ejaecium isolates with high-level 
aminoglycoside resistance. 
3.1 IDENTIFICATION OF ENTEROCOCCI 
3.1.1 API identification 
This is a standardised method consisting of a strip of 20 micro tubes containing dehydrated 
substrates that demonstrates enzymatic activity or the fermentation of sugars. 
The metabolic end-products during the incubation period are either revealed through spontaneous 
coloured reactions or by the addition of reagents. The fermentation tests were inoculated with an 
enriched medium which reconstitutes the sugar substrates. Fermentation of carbohydrates is 
detected by a shift in the pH indicator. These reactions are read by referring to the interpretation 
table and the identification is obtained using the identification table API 20 Strep analytical profile 
index or the API laboratory computer program. 
3.1.2 Identification by conventional biochemical tests 
3.1 .2.1 Salt tolerance test 
Growth in broth and an agar plate containing 6.5% NaCI was determined in brain-heart infusion 
broth base and nutrient agar base respectively. Turbidity in broth and growth on the agar surface 
indicated that the isolates were salt tolerant. A negative reaction is indicated by a lack of turbidity 
and no growth on the agar surface. 
3.1.2.2 Bile aesculin test 
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The bile-aesculin test is based on the ability of certain bacteria notably the enterococci to hydrolyse 
aesculin (1 %) in the presence of 40% bile. Such bacteria produce glucose and aglycone aesculetin. 
Aesculin reacts with an iron salt to form a dark brown or black complex resulting in a diffuse 
blackening of the bile-aesculin medium which contains ferric citrate as the source of ferric irons. 
3.1.2.3 Arginine deamination 
Degradation of arginine results in an increase in pH by the development of a purple colour which 
indicates a positive reaction. A yellow colour indicates a negative result which is due to acid 
accumulation from metabolism of glucose only. 
3.1.2.4 Pyruvate utilization 
Pyruvate is oxidatively decarboxylated by an enzyme system termed the pyruvate dehydrogenase 
complex, producing acetyl-co enzyme A (acetyl CoA). A positive reaction was recorded when the 
indicator changed from green (which is a negative result) to yellow. 
3.1.2.5 Tellurite tolerance 
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Tolerance to tellurite was determined on an agar medium containing 0.04% potassium tellurite. 
Tellurite is reduced to tellurite salts, forming greyish or black colonies after 24-48 hours of 
incubation, indicating a positive reaction. A negative reaction is indicated by no growth on the agar 
surface, or growth without blackening of colonies. 
3.1.2.6 Hippurate hydrolysis 
Hydrolysis of 1 % sodium hippurate tested in broth, results in the production of glycine and sodium 
benzoate. Glycine is deaminated by the oxidising agent ninhydrin, which becomes reduced during 
the process and turns purple, indicating a positive reaction. No colour change (colourless) is 
considered a negative reaction. 
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3.1.2.7 Starch hydrolysis 
Hydrolysis of starch was determined by inoculating a brain- heart infusion agar plate containing 2% 
soluble starch and flooding the surface of the inoculated agar with Gram's iodine. 
Complete clearing indicates hydrolysis of starch which is indicative of a positive reaction. Non 
hydrolysed starch turns a dark blue colour when complexed with iodine, indicating a negative 
reaction. 
3.1.2.8 Voges-Proskauer (VP) test (COBLENTZ) 
The VP test detects the production of acetylmethylcarbinol ( acetoin), an intermediate in the 
formation ofbutylene glycol. In the presence of oxygen and 40% potassium hydroxide (KOH) 
acetoin is oxidised to diacetyl, and a-naphthol which serves as a catalyst to produce a red colour 
complex, which is a positive reaction. A negative reaction is indicated by no colour development 
( colourless). 
3.1.2.9 Carbohydrate fermentation tests (1%) 
The glycolytic pathway, gives rise to pyruvic acid which uses the enzyme lactate dehydrogenase to 
produce lactic acid. A positive reaction appears yellow. The medium remains purple in the absence 
of carbohydrate utilization indicating a negative reaction. 
The following carbohydrates were tested in broth : 
( i ) mannitol 
( ii ) sorbose 
( iii ) sorbitol 
(iv) inulin 
(v) arabinose 
(vi ) melibiose 
(vii) sucrose 
( viii) trehalose 
(ix) lactose 
( x ) glycerol 
(xi) salicin 
(xii) maltose 
( xiii) raffinose 
(xiv) glucose 
3.1.2.10 Test for growth at lOoe and 45°e 
Growth at lOoe and 45°e was determined in brain-heart infusion broth base medium. Growth at 
these temperatures indicated the organisms ability to survive these adverse conditions. 
3.1.2.11 Survival at 60 0 e for 30 minutes 
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Ability of the organism to survive in a water bath at a temperature of 60 ° e for a period of 3 0 
minutes. The presence of bacterial growth indicates the organisms ability to survive at this extreme 
temperature for that period. 
3.1.2.12 Type of haemolysis 
The haemolytic reaction (alpha, beta or gamma) was determined on an agar plate media containing 
5% horse blood. 
Alpha haemolysis: A zone of partial haemolysis or green discoloration occurs in the agar 
immediately surrounding the colony. The red cells membrane remains intact. 
Beta-haemolysis: A distinct zone of total haemolysis of red cells occurs, creating a clear, colourless 
ring surrounding and/or under the colony. The red cells membrane is destroyed. 




Motility which is brought about by rotation of the bacterial flagella was determined in modified 
Difco motility medium. Motile strains grow outward to the edge of the tube and downward towards 
the bottom ofthe tube (a diffuse zone of growth flaring out of the line of inoculation), indicating a 
motile strain. Non motile strains grow on the line of inoculum only. 
3.1.2.14 Detection ofL-pyrrolidonylpeptidase (PYR) 
PYR test is a rapid colourimetric test for use in the differentiation of enterococci from Lancefield 
group D streptococci. The hydrolysis ofL-pyrrolidony-~-naphthylamide, liberates free L-
pyrrolydone carboxylic acid and ~-naphthylamide. Discs impregnated with PYR serve as a substrate 
for the detection ofpyrrolidonylpeptidase. Following inoculation, enzymatic hydrolysis of the 
substrate occurs. The resulting beta-naphylamine forms a red colour complex on addition of a 
colourimetric developer, indicating a positive reaction. No colour change (colourless) is indicative 
of a negative reaction. 
3.1.2.15 Determination of Lancefield group antigen 
The majority of Streptococcus species possess group specific antigens which are usually 
carbohydrate structural components of the cell wall. Lancefield showed that these antigens can be 
extracted in soluble form and identified by precipitation reactions with homologous antisera. The 
Streptex system employs a simple enzyme extraction procedure. Antigen in the resulting extract is 
identified by using polystyrene latex particles coated with group-specific antibodies. The latex 
particles agglutinate strongly in the presence of homologous antigen, and remain in a smooth 
suspension when the homologous antigen is absent. 
[NB: Methods, positive reaction, negative reaction, controls : 
See APPENDIX - Section A] 
3.2 TEST FOR BETA-LACTAMASE PRODUCTION 
3.2.1 Chromogenic Cephalosporin Method 
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The rapid chromogenic cephalosporin method can be used with nitrocefin (Glaxo Ltd). The 
inactivation ofbeta-Iactam antibiotics is by enzymes termed beta-Iactamases which are extra-cellular 
enzymes produced by many strains of bacteria that specifically hydrolyse the amide bond in the beta-
lactam ring of penicillin analogues. The molecule undergoes a distinct colour change from yellow to 
red indicating a positive reaction. A negative reaction is shown by no colour change (remains 
yellow). 
[NB: Method, positive reaction, negative reaction, controls: 
See APPENDIX - Section B] 
3.3 ANTIMICROBIAL SUSCEPTffiILITY TESTING 
3.3.1 Disc diffusion testing 
A standardized inoculum of the organism (l08 CFU/ml) was swabbed onto the surface of a 
Mueller-Hinton agar plate. Filter paper discs impregnated with antimicrobial agents were 
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placed onto the agar. After overnight incubation, the diameter of the zone of inhibition around each 
disc was measured. The size of the zone is inversely proportional to the minimum inhibitory 
concentration ofthe organism. By referring to the NCCLS recommendations for the Kirby-Bauer 
method, or to the "Stokes" criteria for the "Stokes" method, a qualitative report of susceptible, 
moderately susceptible lintermediate or resistant can be obtained. 
Two disc diffusion methods were compared ie. Modified "Stokes" technique and the Kirby-Bauer in 
accordance with standard methods. (91,84). 
Table XII Concentration of antibiotics used for the disc diffusion methods 
1vl0DIFIED "STOKES" KLKBY-BAUER 
ANTmIOTICS TESTED CONCENTRATION CONCENTRATION 
Penicillin lJ-[g 10 units 
Ampicillin 10J-[g 10,ug 
Erythromycin 5,ug and 10 ,ug 5,ug 
Tetracycline 10,ug 30,ug 
Chloramphenicol 10J-[g 30,ug 
Clindamycin 2J-[g 2J-[g 
Fusidic acid 10J-[g 10J-[g 
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1VI0DIFIED "STOKES" KIRBY -BAUER 
ANTIBIOTICS TESTED CONCENTRATION CONCENTRATION 
Cotrimoxazole 25,ug 25,ug 
Rifampicin 5,ug 5,ug 
Ciprofloxacin 5,ug 5,ug 
Cephalothin 30,ug 30,ug 
Cefamandole 30,ug 30,ug 
Cefuroxime 30,ug 30,ug 
Cefoxitin 30,ug 30,ug 
Cefotaxime 30,ug 30,ug 
Gentamicin lO,ug lO,ug 
Tobramycin lO,ug lO,ug 
Netilmicin lO,ug lO,ug 
Amikacin lO,ug 30,ug 
Streptomycin 30,ug 30,ug 
Vancomycin 30,ug 30,ug 
T eicoplanin 30,ug 30,ug 
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Table XIII Comparison of disc diffusion susceptibility testing methods 
MODIFIED "STOKES" KIRBY-BAUER 
MEDIA Mueller-Hinton agar Mueller-Hinton agar 
supplemented with 5% lysed supplemented with 5% lysed 
horse blood horse blood 
INOCULUM Senli-confluentgrowth Inoculum standardized to 
match the turbidity of a 0.5 
McF arland standard 
(approx. 108CFU/rnl) 
U sing a rotary plate method, The medium was inoculated 
control organism S. aureus evenJy over the entire 
NCTC 6571 , was inoculated surface of the agar plate in 
on half of the agar plate and three directions to ensure 
INOCULATION the test organism on the even distribution of the 
OF MEDIA other half. A central band of inoculum. Drug 
3-4mm was left uninoculated impregnated discs were 
between the test and control applied to the agar surface. 
organism to which the 
antibiotic discs were applied. 
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MODIFIED "STOKES" KIRBY -BAUER 
, 
INCUBATION 35-37°C for 16-18 hours in 35-37°C for 16-18 hours in 
an atmosphere of 5-10% an atmosphere of 5-10% 
CO2. CO2. 
CONTROL s.aureusNCTC 657l. S.aureus ATCC 25923 . 
ORGANISMS The control results were 
compared to the NCCLS 
control limit table for 
monitoring antimicrobial 
disc susceptibility zone 
diameter (mm) limits. 
[NB: Detailed methods for disc diffusion susceptibility testing: 
See APPENDIX - Section C] 
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3.3.2 Minimum inhibitory concentration (MIC) 
3.3.2.1 Agar dilution technique 
MICs were measured by means of the agar dilution method in accordance with NCCLS Document 
M2-A4 (83). The agar dilution procedure is a standard reference that quantitatively measures the in-
vitro activity of an antimicrobial agent against the bacterial isolate. Serial two-fold dilutions of each 
antibiotic was made in Mueller-Hinton agar supplemented with 5% lysed horse blood. In addition, 
for the aminoglycosides and cephalosporins Mueller-Hinton agar only was used. Each of several 
concentrations of an antimicrobial agent was incorporated into a tube of molten agar, which was 
then mixed, poured into a petri dish and allowed to solidify. Final plate concentrations ranged from 
256 to O.03,ug/ml. The replicator device of Steers, Foltz and Graves provided standardized 
inoculation of approximately 1 04CFU s of the test and control strains. Inoculated plates were read 
after overnight incubation at 35-37 °C. The MIC was determined by observing the lowest 
concentration of antibiotic that inhibited visible growth ,of the bacterium. Reference strain S. aureus 
ATCC 29213 was used as the control organism. 
3.3.2.2. Broth micro dilution method 
The broth micro dilution method was used to quantitatively measure the in-vitro activity of an 
antimicrobial agent against a bacterial isolate. A sterile plastic micro dilution tray containing various 
concentrations of antimicrobial agents were inoculated with a standardized suspension of the test 
organism. Following overnight incubation at 35-3rC, the MIC was determined by observing the 
lowest concentration of antibiotic that inhibited visible growth of the bacterium. 
[NB: Detailed methods for agar dilution & broth microdilution MIC: 
See APPENDIX - Section D] 
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3.3.3 Minimum bactericidal concentration (MBC) 
Following performance of the microdilution susceptibility test, wells containing concentrations of 
antimicrobial agent equal to and greater than the MIC were sub cultured to determine whether the 
initial inoculum was inhibited from multiplying (bacteriostatic action) or was killed (bactericidal 
action). The MBC test endpoint was determined as the lowest concentration of antimicrobial agent 
that killed ~ 99 .9% of the test inoculum, within a defined period oftime. The reduction is usually 
expressed as the proportion of the inoculum (number of viable colony forming units introduced) that 
is rendered incapable of reproduction on subculture. 
[ Detailed method for minimum bactericidal concentration (MBC) : 
See APPENDIX: Section E ] 
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3.3.4 Breakpoint susceptibility testing 
Breakpoint susceptibility testing refers to a method by which antimicrobial agents are tested only at 
the specific concentrations necessary for differentiating between the interpretive categories of 
susceptible, intermediate and resistant; rather than in the full range of doubling-dilution 
concentrations used to determine MICs. If two appropriate drug concentrations are selected, any 
one of the interpretive categories may be determined. Growth at both concentrations indicates 
resistance, growth only at the lower concentration signifies an intermediate result, and no growth at 
either concentration is interpreted as susceptible. In the breakpoint method of susceptibility testing, 
fixed concentrations of antimicrobial agents are incorporated into agar. The concentrations are 
chosen according to the cut-offpoints of bacterial susceptibility or resistance. The following 






: 16,ug/rnl and 256,ug/rnl 
: 8,ug/ml and 256/Lg/rnl 
: 4/Lg/ml 
: 4/Lg/rnl 
Ciprofloxacin : 1/Lg/rnl and 8/Lg/rnl 
Vancomycin : 4/Lg/rnl 
Teicoplanin : 4/Lg/m1 
Cephalothin : 16/Lg/rnl 
Cefuroxime : 16/Lg/rnl 
Cefamandole : 16/Lg/rnl 
Cefotaxime : 32/Lg/rnl 
Gentamicin : 8/Lg/rnl 
Amikacin : 32/Lg/rnl 
Media used was Mueller-Hinton agar supplemented with 5% lysed horse blood. In addition, 
Mueller-Hinton agar only was used for the aminoglycosides and cephalosporins tested. 
Control organisms s'aureus ATCC 29213, E.coli ATCC 25922 and test organisms were spot 
inoculated with a standardized inoculum of approximately 104CFU on the surface of the agar plate 
using a replicating apparatus. 
Plates were incubated at 35-3rC in an atmosphere of5-1O% CO2 for 18-24 hours. Results were 
recorded as susceptible, moderately susceptible / intermediate or resistant depending on the 
presence or absence of growth for each inoculum spot. 
[NB: Detailed method for breakpoint susceptibility testing: 
See APPENDIX - Section F] 
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3.3.5 Detection of high-level aminoglycoside resistance 
3.3.5 .1 Agar screen technique 
High-level aminoglycoside resistance was detected by assessing growth at high concentrations of 
gentamicin (500 and 2000j.lglml) and streptomycin (2000j.lg/ml) by the standard agar screen 
method. 
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Brain-heart infusion agar plate was divided into 4 quadrants. 3 quadrants were supplemented with 
an aminoglycoside, 500j.lglml of gentamicin, 2000j.lglml of gentamicin and 2000j.lglml of 
streptomycin and the 4th quadrant served as a positive growth control (E.faecalis - MIC 
2048j.lglml) . Each quadrant was inoculated with 1Oj.l1 of a standardized suspension of 108CFU/ml to 
achieve a fmal inoculum of 106CFU/ml. Inoculated medium was incubated at 35-3rC in an ambient 
atmosphere for 18-24 hours. Each quadrant was examined for the presence or absence of bacterial 
growth. Bacterial growth indicated the presence of high-level resistance to either gentamicin, 
streptomycin or both the aminoglycosides. No growth in the presence of the aminoglycosides 
indicated the absence of high-level resistance. 
[NB: Detailed method for high-level resistance to aminoglycosides : 
See APPENDIX - Section F) 
74 
3.3.6 The study of synergism using time-kill curves 
The time-kill curve can be used to study the dynamics of synergism or antagonism for a combination 
of antimicrobial agents by determining the number of viable bacteria remaining over time after 
exposure to each individual antibiotic and various combinations. Time-kill assay data can assess 
both the rate an extent of killing. 
Drug concentrations selected for testing are based on clinical achievable levels in blood. Killing 
curves were performed using the following antibiotics at the stated concentrations. The 
concentration of antibiotics for the beta-Iactams were chosen according to the minimum inhibitory 







: 5,uglml (Fixed) 
: lO,uglml (Fixed) 
: 5,uglml (Fixed) 
: 6,uglml (MIC < 32,uglml) 
50,uglml (MIC 32-128,uglml) 
100,uglml (MIC > 256,ug/ml) 
: lO,uglml (MIC <32,uglml) 
50,uglml (MIC 32-128,uglml) 
lOO,ug/ml (MIC > 256,ug/ml) 
: 10,uglml (MIC < 32,uglml) 
50,ug/ml (MIC 32-128,uglml) 
lOO,uglml (MIC >256,ug/ml) 
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For inoculum preparation colonies of each isolate was grown in brain-heart infusion (BIll) broth at 
35-37°C overnight. Turbidity of an overnight broth culture was adjusted by adding fresh sterile 
broth to match a 0.5 McFarland standard (approx. 108CFU/ml). Inoculum was further diluted to 
achieve a final concentration of 108CFU/ml. 
NB: Prior to inoculation of inoculum, each tube of fresh BIll broth was supplemented with the 
appropriate aminoglycoside, beta-Iactam or glycopeptide antibiotic either alone or in combination. 
At 0,4,24 hour intervals after inoculation, the number of viable CFUs were determined by 
performing serial dilution bacterial colony counts (101-108) . 
By using the viable colony count determined at each time interval, a 24 hour time-kill curve was 
established for each isolate tested. 
Results for the control and each antimicrobial agent concentration, were plotted against time. 
Susceptibility to an aminoglycoside, beta-Iactam or glycopeptide synergy is defined as a > 1 00 fold 
increase in killing by the drug combination over the killing accompanied by the most active of the 
two drugs when tested separately. Resistance to synergy is a <100 fold increase in killing. 
[NB: Detailed method for the study of synergism : 
See APPENDIX - Section H) 
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3.4 TYPING OF ENTEROCOCCI USING PULSED-FIELD GEL ELECTROPHORESIS 
PFGE was performed on 11 enterococcal isolates. Lambda phage DNA concatemers ("lambda 
ladder") was used as a molecular size standard, with the lowest DNA size of 48.5 and the highest of 
532.5 kilobases. 
Seven E.faecalis and 4 E.faecium isolates with different patterns of high-level aminoglycoside 
resistance (gentamicin and / or streptomycin) were chosen. All the E.faecalis strains were 
susceptible to ampicillin and penicillin. PFGE was performed on 3 E.faecium strains that were 
susceptible to ampicillin and penicillin and 1 E.faecium isolate that was resistant to ampicillin and 
penicillin. 
Restriction fragment analysis of genomic DNA was prepared from E.faecalis and Efaecium isolates 
by previously identified methods (79).Briefly, overnight cultures were grown in brain-heart infusion 
(BID) broth and packed cells were suspended in 5ml PIV solution. 2.5ml ofthis suspension was 
mixed with 2.5ml of 1.6% low melting temperature agarose gel and pipetted into small plug molds 
to solidifY. For lysis plugs were placed in lOmllysis solution. 
The lysis solution was then replaced with ESP. Plugs were incubated overnight at 50°C with gentle 
shaking, then washed three times with TE buffer. Enterococcal DNA's were digested with 
restriction enzyme Sma 1 Digestion was performed by placing 1-2mm thick slice of each plug into 
restriction buffer and enzyme, incubated and washed. Plugs were melted at 55-60°C and loaded into 
wells with 1.2% agarose gels in O.5X TBE buffer. 
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Electrophoresis was perfonned with the Contour Clamped Homogenous Electric Field 
apparatus (CHEF-DRIT) by using pulse times beginning with 5 seconds and ending with 35 seconds 
at 200V for 32 hours. Gels were stained with ethidium bromide for 30 minutes, de stained in distilled 
water for 12 hours and photographed with UV radiation. 
[NB. Detailed method for pulsed-field gel electrophoresis : 





All 107 isolates were confirmed to belong to the genus Enterococcus. All the isolates tested positive 
for the group D antigen. A comparison between the API 20 Strep system, with and without the aid 
of the computer software program, and the Facklam identification scheme is shown in the table XIV 
Table XIV Comparison of the API 20 Strep system and the Facklam scheme 
API 20 STREP SYSTEM FACKLAM 
SCHEME 
ORGANISM ANALYTICAL SOFTWARE, PROFILE CONVENTIONAL 
PROFILE INDEX RECOGNITION BIOCHEMICAL 
PROGRAM TESTS 
E.faecalis 65 78 70 
E.faecium 16 16 16 
Egallinarium 2 2 2 
E raffinosus 13 
E casselijlavus 6 
E.faecium 6 
/casselijlavus * 
Isolates not 24 5 
speciated 
* Strains identified as E.faecium with a possibility of being Ecasselijlavus. 
The results were identical with all three systems for 83 (77.5%) of the enterococci. 
The following discrepancies were noted : 
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Thirteen (12.1 %) of the isolates that were identified as Ejaecalis by the API 20 Strep system with 
the computer software program were identified as Eraffinosus by the conventional biochemical 
tests (Facklam). 
Six (5.6%) of the strains identified as Ejaecium/casseliflavus by means of the the computer 
software program were identified as Ecasseliflavus by the Facklam system. 
Five (4.7%) of the isolates that the API 20 Strep system with and without the computer 
identification profile failed to identify, were beta-haemolytic enterococci. 
These 5 strains were identified as Ejaecalis by the Facklam scheme. In addition, of the 24 (22%) 
that were not specified by the analytical profile index, 13(12%) were identified as Eraffinosus, 
6(5.6%) were identified as Ecasseliflavus. 
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4.2 LANCEFIELD GROUPING 
All isolates expressed the group D antigen. 
4.3 BETA-LACTAMASE PRODUCTION 
All enterococcal strains were beta-Iactamase negative 
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4.4 ANTIMICROBIAL SUSCEPTffiILITY TESTING 
Table XV Summary of the two disc diffusion methods 
MODIFIED "STOKES" KIRBY-BAUER 
ANTIBIOTIC S I R S I R 
Penicillin nil 22 85 nil 93 14 
20.6% 79.4% 87% 13.1% 
Ampicillin nil 93 14 nil 93 14 
87% 13% 87% 13.1% 
Imipenem nil 93 14 93 nil 14 
87% 13% 87% 13 .1% 
Piperacillin nil 93 14 85 8 14 
(pipril) 87% 13% 79.5% 7.5% 13 .1% 
Cotrimoxazole 23 55 29 9 nil 98 
21.5% 51.4% 27% 8.4% 91.6% 
Rifampicin nil 65 42 20 12 75 
60.7% 39.3% 18.7% 11.2% 70.1% 
MODIFIED "STOKES" KIRBY -BAUER 
ANTIBIOTIC S I R S I R 
Chloramphenicol 19 65 40 75 11 21 
17.8% 60.7% 37.4% 70% 10% 19.6% 
Clindamycin nil 2 105 nil 8 99 
1.9% 98.1% 7.5% 92.5% 
Tetracycline 43 2 62 43 1 63 
40.2% 1.9% 57.9% 40.2% 0.9% 59% 
Ciprofloxacin nil 73 34 nil 55 52 
68.2% 3l.8% 51.4% 48.6% 
Teicoplanin 107 nil nil nil 107 nil 
100% 100% 
Vancomycin 107 nil nil 107 nil nil 
100% 100% 
S : Susceptible I : Intermediate R: Resistant 
Table XV compares the results for both disc diffusion methods. 
The dicrepancies between the two methods for penicillin and chloramphenicol reflect the higher 
concentrations used by the Kirby-Bauer method as compared to the Stokes method. 
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Although the same concentration of antibiotic was used for cotrimoxazole, rifampicin and 
ciprofloxacin for both methods, the Kirby-Bauer method showed a higher percent of resistance than 
the Stokes method. 
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Table XVI Breakpoint susceptibility test results 
ANTIDIOTIC BREAKPOINTS 
S LLR HLR 
Penicillin ~ 16flglml > 16flg/ml > 256flg/ml 
93 (86.9%) 14(13.1 %) (0%) 
Ampicillin ~ 8flglml > 8flglml > 256flglml 
93(86.9%) 14(13.1%) (0%) 
Imipenem ~ 4flglml > 4flg/ml > 256flglml 
93(86.9%) 14(13.1%) (0%) 
Piperacillin ~ 4flglml > 4flglml > 256flglml 
93(86.9%) 14(13.1%) (0%) 
Ciprofloxacin ~ 1flglml > Iflglml > 8flglml 
(0%) 107 (100%) (0%) 
Vancomycin ~ 4flglml > 4flglml 
107 (100%) (0%) 
Teicoplanin ~ 4jIglml > 4flglml 
107(100%) (0%) 
S : Susceptible LLR : Low-level resisitance HLR : High-level resistance 
Table XVI shows the susceptibility of all strains as obtained with the agar incorporated breakpoint 
methodology. Penicillin, ampicillin and piperacillin showed identical results with 86.9% being 
interpreted as susceptible and 13 .1 % as resistant. None of the isolates grew on the plate containing 
>256flg/ml. This indicates that the MICs were between 32-256flglml. Ciprofloxacin MICs were in the 
range of 2-8flglml. All isolates were susceptible to vancomycin and teicoplanin. 
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Tables XVII, XVIII and XIX show the range, geometric mean and the MIC50 and MIC90 (,ug/ml) of 
all enterococcal species, E. jaecalis, and E. jaecium isolates tested respectively. 
Table XVII Minimum inhibitory concentration (MIC) for all 107 enterococcal species 
MIC (,uglml) 
ANTIBIOTIC RANGE GEOMETRIC 50% 90% 
MEAN 
Penicillin 0.25 - 128 6.76 1 16 
Ampicillin 0.25 - 64 8.35 0.5 16 
Imipenem 0.25 - 128 6.66 1 32 
Vancomycin 0.5 - 4 9.92 1 2 
Teicoplanin 0.25 - 1 8.85 0.5 1 
Table XVIII Minimum inhibitory concentration (MIC) for E.faecalis (70 isolates) 
MIC (,ug/ml) 
ANTIBIOTIC RANGE GEOMETRIC 50% 90% 
MEAN 
Penicillin 0.25 - 16 5.96 1 1 
Ampicillin 0.25 - 1 7.61 0.5 0.5 
Imipenem 0.25 - 1 9.34 1 1 1 
Vancomycin 0.5 - 4 8.56 1 2 1 
Teicoplanin 0.25 - 1 9.56 0.5 1 
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Table XIX Minimum inhibitory concentration (MIC) for E.faecium (16 isolates) 
MIC (/-Lg/ml) 
ANTIBIOTIC RANGE GEOMETRIC 50% 90% 
MEAN 
Penicillin 0.5 - 256 5.02 16 64 
Ampicillin 0.5 - 64 5.78 16 32 
Imipenem 0.5 - 128 5.78 16 32 
Vancomycin 0.5 - 2 7.10 1 2 
T eicoplanin 0.5 - 2 7.25 0.5 2 
All 3 beta-Iactams showed similar results. When one compared the Efaecalis and Efaecium 
isolates, the Efaecalis were fully susceptible but many of the Efaecium strains were resistant. The 
glycopeptides showed similar results for both the species. 
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Fig.8 Comparison of the distribution of minimum 
inhibitory concentration (MIC) and minimum 
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Fig.9 Comparison of the distribution of minimum 
inhibitory concentration (MI C) and minimum 
bactericidal concentration (MBC) for teicoplanin 
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Tables XX, XXI, XXII and XXIII show the influence oflysed blood on the susceptibility test 
results of aminoglycosides and cephalosporins. Gentamicin, tobramycin and netilmicin showed a 
high percent offalse susceptibility for the Stokes, Kirby-Bauer, Breakpoint and MIC methods. The 
aminoglycoside that was unaffected by the presence of blood in all methods was amikacin. 
Cephalothin, cefamandole and cefuroxime were not significantly affected by the addition of blood to 
the medium. The cephalosporin that showed a high percent of false susceptibility in all four methods 
in the presence of lysed blood was cefotaxime. 
Table XX Comparison of susceptibility testing of aminoglycosides and 
cephalosporins with MueUer-Hinton agar with and without the presence of 
5% lysed blood (Stokes) 
ANTIBIOTIC MUELLER-HINTON AGAR MUELLER-HINTON AGAR 
+5% LYSED BLOOD ONLY 
S I R S , I R 
Gentamicin 52 8 47 nil 6 101 
(48.6%) (5.6%) (43.9%) (5.6%) (94.4%) 
Tobramycin 38 2 67 nil nil 107 
(35.5%) (4.7%) (62.9%) (100%) 
Netilmicin 36 6 65 nil 4 103 
(33.6%) (5.6%) (60.7%) (3.7%) (96.3%) 
Amikacin nil nil 107 nil nil 107 
(100%) (100%) 
Cefotaxime 32 3 72 nil 5 102 
(29.9%) (2.8%) (67.3%) (4.7%) (95.3%) 
Cefamandole nil 50 57 nil 45 63 
(46.7%) (53.3%) (48.6%) (60.7%) 
Cefuroxime 20 nil 87 nil 3 104 
(18.7%) (81.3%) (2.8%) (97%) 
Cephalothin nil 60 47 nil 56 61 
(56.1 %) (43.9%) (52.3%) (48.7%) 
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Table XXI Comparison of susceptibility testing with Mueller-Hinton agar (MHA) 
supplemented with 5% lysed horse blood and Mueller-Hinton agar only for 
aminoglycosides and cephalosporins (Kirby-Bauer) 
MUELLER-lllNTON AGAR MUELLER-lllNTON AGAR 
+5% LYSED BLOOD ONLY 
ANTIBIOTIC S I R S I R 
Gentamicin 55 20 32 nil 26 81 
(51.4%) (18.7%) (29.9%) (24.3%) (75.7%) 
Tobramycin 35 9 63 nil 7 100 
(32.7%) (8.4%) (58.9%) (6.5%) (93.4%) 
Netilmicin 33 7 67 nil 9 98 
(30.8%) (6.5%) (62.6%) (8.4%) (91 .6%) 
Amikacin nil nil 107 nil nil 107 
(100%) (100%) 
Cefotaxime 30 1 76 nil 1 106 
(28%) (0.9%) (71%) (0.9%) (99. 1%) 
Cefamandole 5 5 97 nil 2 105 
(4.7%) (4.7%) (90.6%) (1.9%) (98.1%) 
Cefuroxime 18 nil 89 nil 2 105 
(16.8%) (83 .2%) (1.9%) (98.1%) 
Cephalothin 5 45 57 nil 48 59 
(4 .7%) (42%) (53.2%) (44.8%) (55 .1%) 
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Table XXII Comparison of aminoglycoside and cephalosporin results with Muller-
Binton agar (MHA) supplemented with 5% lysed horse blood and Mueller-
Binton agar only (Breakpoints) 
MUELLER-HINTON AGAR MUELLER-HINTON AGAR 
+5% LYSED BLOOD ONLY 
ANTIBIOTIC S R S R 
Gentamicin :-:; 16fLg/ml ~ 32fLg/ml :-:; 16fLg/ml ~ 32fLg/ml 
57(53.3%) 50(46.7%) 4(3.7%) 103(96.3%) 
Tobramycin :-:;4fLg/ml ~ 8fLg/ml :-:; 4fLg/ml ~ 8fLg/ml 
44(41%) 63(58.9%) (0%) 107(100%) 
Netilmicin :-:; 8fLg/ml ~ 16fLg/ml :-:; 8fLg/ml ~ 16fLg/ml 
40(37.4%) 67(62.6%) (0%) 107(100%) 
Amikacin :-:; 16,ug/ml ~ 32,ug/ml :-:; 16,ug/ml ~ 32,ug/ml 
(0%) 107(100%) (0%) 107(100%) 
Cefotaxime :-:; 8fLg/ml ~ 32fLg/ml :-:; 8fLg/ml ~ 32fLg/ml 
30(28%) 77(72%) 2(4.7%) 105(98.1%) 
Cefamandole :-:; 8fLg/ml ~ 16fLg/ml :-:; 8fLg/ml ~ 16fLg/ml 
5(4.7%) 102(95 .3%) 5(4.7%) 102(95 .3%) 
Cefuroxime :-:; 8fLg/ml ~ 16,ug/ ml :-:; 8,ug/ml ~ 16,ug/ml 
18 (16.8%) 89(83 .2%) 2(4.7%) 105(98.1%) 
Cephalothin :-:;8,ug/ml ~ 16fLg/ml :-:; 8,uglml ~ 16fLglml 
55(51.4%) 52(48 .6%) 52(48.6%) 55(51.4%) 
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Table XXIII Comparison of aminoglycosides and cephalosporins on Mueller-Hinton 
agar (MHA) only and Mueller-Hinton agar supplemented with 5% lysed 
horse blood (MIC) 
MUELLER-HINTON AGAR MUELLER-HINTON AGAR 
+5% LYSED BLOOD ONLY 
MIC (f-tg/ml) NilC (f-tg/ml) 
ANTIBIOTIC RANGE 50% 90% RANGE 50% 90% 
Gentamicin 4 - >256 4 >256 8 - >256 16 >256 
Tobramycin 4- >256 8 >256 8 - >256 32 >256 
Netilmicin 4- >256 8 >256 8 - >256 32 >256 
Amikacin 32 - >256 64 >256 32 - >256 64 >256 
Cefotaxime 8 - >256 8 >256 16->256 64 >256 
Cefamandole 8 - >256 64 >256 16 - >256 64 >256 
Cefuroxime 8 - >256 16 >256 16- >256 64 >256 
Cephalothin 8 - >256 32 >256 16 - >256 32 >256 
93 
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4.5 mGR-LEVEL AMINOGLYCOSIDE RESISTANCE 
Table XXIV Results of high-level aminoglycoside resistance 
ORGANISM GENTA (500 STREPTO GENTAAND TOTAL 
and 2000,ug/ml) (2000,ug/ml) STREPTO RESISTANCE 
Ejaecalis (n=70) 2 (2.8%) 5(7.1%) 15 (2l.4%) 22 (31.4%) 
Ejaecium (n=16) 4 (25%) 5 (3l.2%) 9 (37.5%) 
E casseliflavus( n=6) 1 (16.7%) 1 (16.7%) 3 (50%) 5 (83%) 
Eraffinosus (n=13) 1 (7.7%) 1(7.7%) 2 (15.4%) 
Egallinarium (n=2) 1 (50%) 1 (50%) 
n = total number of isolates tested. 
The results of the detection for high-level aminoglycoside resistance are shown in Table XXIV 
Isolates that were resistant to 500,ug/ml of gentamicin were also resistant to 2000,ug/ml. 
Thirty-nine (26.4%) ofthe 107 enterococci tested displayed high-level aminoglycoside resistance. 
Three (2.8%) of the isolates showed high-level resistance to gentamicin only, 11 (10.3%) to 
streptomycin only and 25 (23 .4%) to both gentamicin and streptomycin. 
4.6 THE STUDY OF SYNERGISM 
Figs. 10.1 to 17.3 show time-kill synergy studies of ampicillin, penicillin, imipenem, 



















Fig 10.1 Time kill study showing synergism against E.faecalis displaying lew-Ievel resistance to 


























Fig. 10.2 Time-kill curves showing imipenem plus gentamicin displaying synergism against E.faecalis. This isolate 
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Fig. 10.3 Time kill study showing synergism with vancomycin or teicoplanin in combination with gentamicin. 

























Fig. 11.1 Time-kill study curves showing synergism of ampicillin and penicillin in combination with gentamicin. This 
E.faecalis isolate showed low-level resistance to gentamicin 
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Fig. 11.2 Time-kill study showing synergism against E.faecalis with imipenem in combination with gentamicin. This 
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Fig.11 .3 Vancomycin or teicoplanin displaying synergism in the time-kill study when combiood with gentamicin against 
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Fig.12.1 Time-kill study of E.faecalis in the presence of high-level gentamicin resistance shows ampicillin combined with 
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Fig.12.2 Time kill study showing synergism when vancomycin or teicoplanin were combined with penicillin against 
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Fig.12.3 Imipenem and vancomycin or teicoplanin showing synergism against Efaecalis in the presence of high-level 
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Fig.13.1 Time-kill study of E.faecalis showing synergism of ampicillin and vancomycin or teicoplanin. This isolate 
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Fig.13.2 Penicillin in combination with vancomycin or teicoplanin displaying synergism in the time-kill study of 
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Fig.13.3 Time kill study showing synergism against E.faecalis in the presence of high-level gentamicin resistance 
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Fig.14.1 Time kill study ofE.faecium failing to show synergism. An additive phenomenon was noted with ampicillin or 
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Fig.14.2 Time-kill study showing an additive effect against Efaecium when combined with imipenem and 
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Fig.14.3 Vancomycin or teicoplanin when combined with gentamicin displaying an additive phenomenon against 
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Fig.1S.1 Time-kill study showing synergism against E.faecium when ampicillin or penicillin was combined with 
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Fig.1S.2 E.faecium isolate displaying synergism when combined with imipenem and gentamicin as shown by the time-kill 
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Fig.1S.3 Time-kill study displaying synergism against E.faecium with low-level gentamicin resistance when 
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Fig .16.1 Time-kill curves showing an additive action against E.faecium when ampicillin was combined with vancomycin 
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Fig.16.2 Time-kill study showing an additive phenomenon against E.faecium when penicillin was combined with vancomycin 
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Fig.17.1 Time-kill study showing an additive effect when ampicillin was combined with the glycopeptides. This E.faecium 
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Fig.17.2 Vancomycin and teicoplanin showing an additive effect against E.faecium which was highly resistant to gentamicin 
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Fig.17.3 Time-kill curves showing an additive effect against E.faecium when imipenem was combined with vancomycin or 
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The time-kill studies suggest that penicillin, ampicillin or imipenem that were susceptible when 
combined with gentamicin displayed synergy against Ejaecalis with low-level gentamicin 
resistance (MIC~ 500/Lglml), and showed susceptibility to these beta - lactams ( MIC~ l/Lglml). 
In the presence of high-level gentamicin resistance (MIC ~2000/Lglml), beta-Iactam susceptible 
Efaecalis (MIC ~ l/Lglml), when exposed to a combination of the beta-lactams and 
glycopeptides, displayed synergism. 
Time-kill studies performed on Efaecium isolates with high-level resistance to ampicillin, 
penicillin, imipenem (MIC 32-128/Lg/ml) and gentamicin (MIC ~2000/Lg/ml) showed an additive 
effect only, although an increased concentration of the beta-lactams were used. 
Ampicillin, penicillin or imipenem combined with vancomycin also failed to show synergy against 
these Ejaecium isolates. The result was an additive effect although the isolates were susceptible 
(MIC's of ~ l/Lglml) to the glycopeptides. 
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4.7 PULSED-FIELD GEL ELECTROPHORESIS 
Plates 1 and 2 show chromosomal digestion patterns of Efaecalis and Efaecium. 
Plate 1 Pulsed-field gel electrophoresis of Sma I digested chromosomal DNA of E.faecalis 




The restriction endonuclease digestion patterns of Efaecalis isolates studied are shown in plate 1. 
The molecular sizes are given in the left-hand margin as kilobases (kb). Lane a shows the lambda 
ladder standard (A concatemer). Lanes b, c and d show isolates that displayed high-level resistance 
to gentamicin and streptomycin. Lane e shows the negative control (TBE buffer). Lanes f and g 
were Efaecalis isolates that showed high-level resistance to gentamicin. Lanes hand i were 
strains that were highly resistant to streptomycin. 
Plate 2 shows the pulsed-field gel electrophoretic patterns of SmaI digested chromosomal DNA 
from isolates of Efaecium. Lanes a and h show the lambda ladder standard (A concatemer). Lane 
b displayed an isolate showing high-level resistance to gentamicin and streptomycin. 
Lane c was the TBE buffer (control). Lane d, e and f showed Efaecium isolates that displayed 
high-level resistance to gentamicin. 
Results of the genetic study showed that there was a wide variation in the restriction endonuclease 





The genus Enterococcus contains Gram positive cocci that are presumptively identified by their 
ability to hydrolyse aesculin and their tolerance to 40% bile and 6.5% NaCl. They are further 
identified by their ability to grow at extreme temperatures of 10 and 40 ° C and survive for a period 
of30 minutes at 60°C. Most enterococci contain the Lancefield group D antigen. Hydrolysis of 
pyrrolidonyl-p-naphthylamide (PYR) is a characteristic feature that is also seen with group A 
streptococci but not with other streptococci. 
Although the above screening tests appeared to be sufficient in the past to identify enterococci 
presumptively it is now recognised that other less commonly encountered Gram positive cocci can 
also give a positive reaction in some of these tests. 
For example, some Lactococcus, Aerococcus, Pediococcus and Leuconostoc species are bile 
aesculin positive or can grow in 6.5% NaCI or both. Strains of Pediococcus and Leuconostoc 
species can react with Lancefield group D antigen and some Lactococcus and Aerococcus species 
are PYR positive. 
In serious infections such as endocarditis, differentiation between E.faecalis and E.faecium (the 2 
most commonly encountered enterococcal species) can be useful because of the naturally 
occurring differences in the susceptibility patterns of these species. E casseliflavus and E.faecium 
showed similar susceptibility patterns. E.faecalis, E raffinosus and Egallinarium differed only 
slightly in their susceptibility patterns. 
Also important for species identification of enterococci is that it may be useful for epidemiologic 
surveillance in hospitals. 
Studies have shown that the Enterococcus is a nosocomially spread pathogen (78,91, 116). 
Speciation and further typing within a genus assists in outbreak control. 
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The API 20 Strep system using the analytical profile index or the software profile recognition 
program to identify the enterococci was not able to identify the less common species accurately ie. 
E.casseliflavus, E.raffinosus and the beta-haemolytic enterococci. 
It is important to note that some of the commercial or computer software identification systems 
for the species of enterococci were probably evaluated before some of the newer species were 
recognised and may therefore not be accurate. 
By using the conventional identification system devised by Facklam and Collins, most if not all 
enterococci can be easily identified to species level. Fifteen biochemical tests which are easily 
prepared in the laboratory are used for this identification system. These media are cheaper than 
the API identification strips. 
If the Enterococcus belongs to one of the common species such as Ejaecalis or Ejaecium the 
API 20 Strep system or the Facklam scheme would be able to accurately identify the isolate. In 
the case of one of the uncommon species of enterococci the best system to use is the Facklam 
scheme since it only requires the availability of the Facklam media. Laboratories should therefore 
consider using this system. 
5.2 ANTIMICROBIAL SUSCEPTmILITY TESTING 
5.2.1 Susceptibility tests results 
One of the most important factors in in-vitro testing for antimicrobial activity is the 
standardization of the method used. This is achieved by the use of a control (ATCC or NCTC) 
bacterial organism. It is the correct susceptibility test result that is useful in predicting the 
response of the patients treated with the appropriate antimicrobial agents. 
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In a diagnostic laboratory, a convenient method of performing antimicrobial susceptibility testing 
is required and in one form or another a disc-diffusion method is most commonly used. It is less 
time consuming and easily performed in the laboratory. 
Common problems encountered with the disc-diffusion tests is the inactivation of labile antibiotics 
such as co-amoxiclav, due to inadequate storage or handling in the laboratory. This may be 
indicated by a gradual decrease in zone size. Too heavy or too light an inoculum may be indicated 
by a general decrease or increase in zone sizes. Errors in transcribing the result or measuring zone 
sizes may also occur. Problems with medium may be encountered ego high pH will produce larger 
zones with aminoglycosides and erythromycin and smaller zones with tetracycline and fuscidic 
acid. The reverse may occur if the pH is too low. 
The two disc-diffusion methods compared were Kirby-Bauer and Stokes method. Both the 
methods showed similar results for most of the antibiotics tested. The 3 antibiotics that showed a 
discrepancy between the two methods were penicillin, chloramphenicol and cotrimoxazole. This is 
because of the higher breakpoint used for the Kirby-Bauer method which resulted in a much 
higher percent of the isolates being susceptible. For ciprofloxacin the same concentration of 
antibiotic is used for both the methods but the Stokes method showed a slightly higher percent of 
resistance than the Kirby-Bauer method. 
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In the breakpoint method of susceptibility testing fixed concentrations of antimicrobial agents are 
incorporated into the agar. One or more concentration of an antibiotic chosen is intended to 
conform to agreed cut -off points of bacterial susceptibility or resistance. 
The breakpoint method has considerable practical advantages. Large numbers of isolates can 
easily be tested by the use of a multi-point inoculation technique. The clear cut end-points ie. 
either growth or no growth of a bacterial isolate removes interpretation difficulties. 
The chief disadvantage of this method is that it does not provide information as to whether an 
organism is highly susceptible or highly resistant; this limitation is usually important in the 
assessment of degrees of resistance. 
Clerical errors can be made in transcribing the results from the multi-point inoculating plates since 
the isolates inoculated are very close together. 
Comparison of the Stokes disc diffusion with the breakpoint method results for penicillin showed 
that 79.4% were resistant with the disc diffusion test and only 13.1 % with the breakpoint method. 
This discrepancy is because of the lower concentration of penicillin used for the Stokes method. 
The Kirby-Bauer disc diffusion and the breakpoint methods showed identical susceptibility test 
results for penicillin with only 13 . 1 % being interpreted as resistant. Both the disc diffusion 
methods and the breakpoint method showed identical results for ampicillin, imipenem, piperacillin, 
vancomycin and teicoplanin. 
To quantitatively measure the in-vitro activity of an antimicrobial agent against a bacterial culture, 
a broth or agar dilution technique may be used to determine the minimum inhibitory concentration 
of an antibiotic (MIC). 
MICs are still generally considered to be the reference standard for comparison and evaluation 
of other susceptibility tests and the efficacy of all antimicrobials are described in terms of MIC. 
128 
The greatest use of the MIC is to compare new antimicrobial agents against a battery of bacterial 
strains. 
However, MIC values are still required in routine laboratories as a guide for determining therapy 
whenever the susceptibility of a pathogen is unpredictable ie. it is difficult to determine whether 
that isolate is susceptible, intermediate or resistant by means of breakpoint methodology (disc 
diffusion or agar incorporation). 
MIC values are also important when an infection is not responding to apparently appropriate 
therapy particularly when the organism is reported being susceptible to the antibiotics tested. 
Louie et aI., reported that the MICso and MIC90 (tlg/ml) for 34 Ejaecalis strains tested for 
ampicillin was 2 and 4tlg/ml, imipenem 8 and 16,ug/ml, vancomycin 2 and 4tlg/ml and teicoplanin 
0.25 and 0.5tlg/ml respectively. For the 103 E.faecium strains, the MICso and MIC90 (,ug/ml) for 
ampicillin was 8 and 64tlg/m1, imipenem was 32 and >64,ug/ml, vancomycin was 2 and 8tlg/ml 
and teicoplanin was 0.5 and 1tlg/ml respectively (58) . 
Gordon et ai., showed lower MICso and MIC90 (tlg/ml) results than those cited by Louie et al. 
They tested 633 E.faecalis isolates. MICso and MIC90 (tlg/ml) for penicillin was 2 and 4tlg/ml, 
ampicillin was 1 and 2tlg/ml, imipenem was 1 and 2tlg/ml, vancomycin was 2 and 4,ug/ml and 





and MIC90 (,uglml) for the 58 Ejaecium strains tested were as follows :penicillin 32 
and >128,uglml, ampicillin 8 and 64,uglml, imipenem 16 and 32,uglml, vancomycin 1 and 2,uglml 
and teicoplanin 0.5 and 1,uglml respectively (33). 
Our studies showed that the 70 Ejaecalis isolates tested had identical MIC50 and MIC90 (,uglml) 
results, for penicillin, ampicillin and imipenem. MIC50 and MIC90 (,uglml)for penicillin and 
ampicillin was 1 ,uglml and imipenem was 0.5,ug/ml. 
The MIC50 ,uglml for the Ejaecium strains tested was 16 ,ug/ml for the beta-Iactams and the 
MIC90 (,uglml) was 64 ,uglml for penicillin and 32 ,uglml for ampicillin and imipenem. The 
Ejaecium MIC50 and MIC90 (,ug/ml) were much higher than the Ejaecalis isolates (33,58). Our 
results were similar to those reported by Gordon et al., (33) . 
5.2.2 Effect of blood in the medium for susceptibility testing 
Jenkins et al. reported that disc diffusion tests on 5% sheep blood enriched Mueller-Hinton agar 
gave enlarged zone sizes that falsely indicated susceptibility (40) . For gentamicin and tobramycin 
70% and 72% respectively of the isolates changed from susceptible to resistant when these 
isolates were tested on Mueller-Hinton agar only (40). Amikacin showed a false susceptibility of 
4% and kanamycin 2% on media supplemented with blood; agar dilution MIC' s for gentamicin 
and tobramycin showed only 6-10% false susceptibility (40) . 
Amikacin and kanamycin MICs remained the same or decreased by one dilution only on 
unsupplemented media (40). In most cases the discrepancy was not sufficient to change the MIC 
interpretation. 
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Results obtained in this study for the aminoglycosides on blood enriched media for both the disc 
diffusion methods showed a false susceptibility of 50% for gentamicin and 32% for tobramycin 
and netilmicin. 
With the breakpoint method the presence of blood showed a false susceptibility of 49.6%, 41 % 
and 37.4% for gentamicin, tobramycin and netilmicin. Amikacin remained unaffected. 
MIC results obtained in this study confirmed this. Gentamicin, tobramycin and netilrnicin dilutions 
were two fold lower and arnikacin was unaffected when tested on Mueller-Hinton agar +5% lysed 
blood. 
It has been reported that the presence of 5% lysed blood and the type of culture media used give 
false susceptibility test results for certain second and third generation cephalosporins (98,109). 
Disc-diffusion comparison ofthe Ejaecalis tested by Sahm et al. (45 strains) on media 
supplemented with blood showed discrepancies that did not exceed 4% for cephalothin, 
cefamandole, cefoperazone (98,109). In contrast, there was a much greater discrepancy 18% for 
cefotaxime and 14% for cefuroxime, ceftizoxine (98,109). 
MICs for cephalothin, cefamandole, cefoperazone were not substantially influenced by the type of 
culture media or the addition of blood to the medium. MICs remained the same or was one 
dilution lower (98,109). 
Comparitively, MICs for cefuroxime, ceftizoxime, ceftriaxone and cefotaxime varied both with a 
brand of media used and the addition of 5% lysed blood. MICs wer.e 8-16 times greater with 
blood supplemented media (98,109). 
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Results obtained in this study for both the disc diffusion methods showed very similar results on 
blood enriched media for the cephalosporins. 
Cefotaxime was the only cephalosporin that was greatly affected, showing a false susceptibility of 
29%. Cefuroxime was less affected with a false susceptibility of 18%. 
Cefotaxime was also the only cephalosporin that was greatly affected by the presence of blood in 
the medium with the breakpoint method, resulting in a false susceptibility of23.3%. Cefuroxime 
displayed a false susceptibility of 12.1 %, cefamandole was unaffected and the cephalosporin that 
was slightly affected 2.8% was cephalothin on blood enriched media. 
Results of this study for MICs showed that the only cephalosporin that was markedly affected by 
blood supplemented media was cefotaxime. The MIC was 3 times lower on unsupplemented 
media. MICs for cefamandole and cephalothin with and without blood remained the same except 
for cefuroxime that was 2 dilutions lower in the presence of media supplemented with 5% lysed 
blood. 
It is important to note that false susceptibility in the presence of blood for enterococci does occur 
with certain aminoglycosides and cephalosporins. According to Sahm et at. (98), false 
susceptibility was shown to be caused by heme. It has been postulated that the heme effect is 
related to the catalytic cleavage of intracellular H20 2 which results in lipid peroxidation which 
reduces zones of inhibition. 
Enterococci grow well and give accurate susceptibility results on Mueller-Hinton agar without 
blood supplementation and because of the problem of false susceptibility with certain 
aminoglycosides and cephalosporins, it is recommended that enterococci routinely be tested on 
media without the addition of blood. 
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5.3 mGR-LEVEL AMINOGLYCOSIDE RESISTANCE 
Recognition of the importance of high-level aminoglycoside resistant enterococci 
(MIC ~ 2000tlg/rnl) has clearly increased during this past decade. Medical centres in the United 
States and elsewhere are reporting resistant rates ranging from 4.5 to 55% (42,61,117). 
Keddy et al. from Johannesburg in South Africa showed that the high-level gentamicin resistance 
was 26.5% for E.faecalis and 20% for E.faecium isolates. 144 E.faecalis and 15 E.faecium 
strains were tested (113). 
The results of this study showed that 39 (36.4%) of the enterococci tested displayed high-level 
resistance to gentamicin and streptomycin. All isolates that were resistant to 500tlg/rnl of 
gentamicin were also resistant to 2000tlg/rnl of gentamicin. A lower concentration of gentamicin 
ie .500.ug/rnl is a good screen to detect high-level gentamicin resistance. 
The aminoglycoside inactivating enzyme that is responsible for streptomycin high-level resistance 
is the phosphorylating enzyme (APH3 "). The acetylating enzyme, AAC' inactivates gentamicin 
and tobramycin. AAC6', another acetylation enzyme confers high-level resistance to gentamicin, 
amikacin, tobramycin and kanamycin. 
AAC3-1, AAC3-2 inactivates gentamicin, tobramycin and kanamycin. 
The adenylating enzyme, ANT2" confers high-level resistance to gentamicin, tobramycin and 
kanamycin. Streptomycin is also inactivated by the adenylating enzyme AAD3" (66). Since most 
clinical laboratories do not perform full MICs routinely and certainly not synergism studies, 
screening tests that predict high-level aminoglycoside resistance should be routinely performed 
considering the high percent of aminolglycoside resistance being observed. 
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A number of simple screening methods are available for detecting the presence of high-level 
aminoglycoside resistance. These methods include a disc diffusion method using high content 
aminoglycoside discs, a broth or agar screen supplemented with a particular aminoglycoside to a 
final concentration of 500 and/or 2000,uglml and finally more recently the introduction of the 
Etest. According to Leclercq et al. high-level resistance to aminoglycosides in enterococci is 
conveniently detected by the disc diffusion technique using high content discs with a concentration 
of 1000,ug for streptomycin and 500,ug for gentamicin (51). 
Lower concentrations of aminoglycosides may also be used to detect aminoglycoside resistance as 
based on the concentrations chosen by Rosenthal and Freundlick ie. 120,ug for gentamicin and 
300,ug for streptomycin (95). 
According to Sahm et aI., discs can accurately discriminate between low-level and high-level of 
resistance. Zone diameters of s; 6-7mm for the 300 and 120,ug discs is a reliable indicator of 
aminoglycoside resistance. Zone diameters of z 10 is indicative of synergy susceptibility ie. these 
isolates show synergy with a beta - lactam aminoglycoside combination (95). A zone diameter of 
< Ilmm is indicative of high-level gentamicin resistance and a zone diameter of < 12 is indicative 
of high-level streptomycin resistance when using a high content disc of 500,ug (51). 
If there is no growth after 24 hours, it is advisable to reincubate the agar plates or broth for a 
further 24 hours before final results can be determined (3). About 95% of the isolates that were 
tested showed growth in 24 hours, only 5% showed growth after a further 24 hour incubation. 
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There is usually little need to test aminoglycosides other than streptomycin and gentamicin since 
these are the two agents for which there are most clinical data and are most commonly used for 
synerglsm. 
Most gentamicin resistant organisms described thus far, are also highly resistant to kanamycin, 
amikacin, tobramycin and netilmicin, therefore there is no indication for routine testing of these 
agents (66). 
High-level gentamicin resistance makes it difficult to identify a regimen that will be bactericidal. 
This difficulty is compounded by the increasing frequency of acquired resistance to beta-Iactams 
and glycopeptide agents among enterococci. 
The consequence of such resistance for effective treatment of serious enterococci infections 
makes screening designed to detect high-level amino glycoside resistance among the most relevant 
of the susceptibility testing procedures performed. It is thus recommended that all enterococcal 
isolates be screened for high-level aminoglycoside resistance especially where synergism between 
a beta-Iactam and an aminoglycoside will be required such as for bacterial endocarditis. Evaluation 
apd establishment of test accuracy when performing screening for high-level aminoglycoside 
resistance is therefore of major importance. 
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5.4 BETA-LACTAMASE PRODUCTION 
For susceptibility testing, inoculum should be approximately 107-108CFUs/ml for the organism to 
produce a large enough amount of enzyme that can inactivate the antibiotic and thus make it 
resistant. 
Whether all ampicillin susceptible enterococci should be tested for the production of beta-
lactamase is still debatable. Beta-Iactamase producing strains may remain undetected since disc 
susceptibility may fail to detect those isolates if the inoculum size is too low ie. < 106 CFU/ml. 
It seems reasonable however, to test all enterococcal isolates for beta-Iactamase production from 
very serious infections such as bacterial endocarditis. Testing with the chromogenic 
cephalosporin, nitrocephin is a simple method which can be easily performed in the laboratory. 
All isolates tested were beta-Iactamase negative, how long it would remain so locally is yet to be 
seen. 
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5.5 THE STUDY OF SYNERGISM 
Time-kill studies were performed on 4 Ejaecalis isolates and 4 Ejaecium isolates to determine 
the minimal concentration required to obtain a synergistic effect with a fixed concentration of 
5/Lg/ml for gentamicin and teicoplanin and 10/Lg/ml for vancomycin. 
According to the minimum inhibitory concentration (MIC) of the isolates, the following 
concentration of antibiotics were chosen for ampicillin, penicillin and imipenem. 
6-1O/Lg/ml : MIC ofless than 32/Lg/ml. 
50/Lg/ml : MIC between 32 and 128/Lg/ml. 
100/Lg/ml : MIC of greater than or equal to 256/Lg/ml 
From the time-kill study graphs it was seen that in the enterococcal isolates that were susceptible 
to ampicillin, penicillin and imipenem (MIC ::0; 1 /Lg/ml), with low-level gentamicin resistance 
(MIC ::0; 500/Lglml) showed effective synergistic killing by the combination of ampicillin plus 
gentamicin or penicillin plus gentamicin. Thus the combination of ampicillin plus gentamicin or 
penicillin plus gentamicin showed a synergistic effect. lmipenem plus gentamicin has not been 
often used, thus clinical data is lacking, but could be successfully used judging by the results. 
Ampicillin and penicillin alone also produced very good activity on all the Ejaecalis isolates 
tested as was demonstrated by the time-kill synergy studies. 
Ampicillin, penicillin or imipenem (MIC <1.0/Lglml) in combination with the glycopeptides 
displayed synergism in the presence of high-level gentamicin resistance (MIC ~ 2000/Lg/ml). 
Vancomycin or teicoplanin combined with an amino glycoside provides an effective alternative 
therapy for serious life threatening infections that occur in patients that cannot tolerate the 
penicillin-class antibiotics. 
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The glycopeptides are also recommended as the drugs of choice for treatment of enterococci with 
high-level ampicillin and penicillin resistance (MIC ;;>: 1 28,uglml) . Vancomycin and teicoplanin 
alone showed very good activity against all the E.faecalis isolates tested. 
For the one E.faecium strain that had an MIC of l024,uglml for gentamicin, 32,uglml for 
ampicillin, 128.0,ug/ml for penicillin and imipenem, a higher concentration of ampicillin, penicillin 
and imipenem (SO,uglml) was needed for the time-kill study. In this setting even the increased 
concentration of antibiotic still failed to show synergism between ampicillin, penicillin or imipenem 
plus gentamicin. An additive or indifferent interaction was observed. 
Although the MIC for vancomycin and teicoplanin for this isolate was susceptible (MIC 1.0 and 
O.2S,uglml respectively), synergism was not observed between the glycopeptides plus gentamiciJ;l. 
This combination also appeared indifferent. 
Time-kill studies were performed on an E.faecium isolate that had an MIC of 64. O,uglml for 
ampicillin and 128.0,uglml for penicillin and imipenem indicating resistance. This strain also 
displayed high-level gentamicin resistance (MIC ;;>: 2000,ug/ml). Due to the high MIC values, 
SO,uglml of ampicillin, penicillin and imipenem was used for the time-kill studies. This isolate 
produced an additive effect only. 
Synergy studies combining anyone of these beta-Iactams with gentamicin showed no synergy; 
only an additive effect was observed. 
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The combination of ampicillin, penicillin or imipenem plus vancomycin or teicoplanin also resulted 
in the lack of synergism although vancomycin and teicoplanin had susceptible MIC values (1.0 and 
O.Sj..lg/ml respectively). 
One-hundred j..lglml of ampicillin, penicillin and imipenem were used for time-kill testing of a very 
resistant E.faecium strain with a MIC of 64j..lglml for ampicillin, 2S6uglml for penicillin and 
imipenem. This isolate also had a gentamicin MIC of ~2000j..lglml . The isolate was susceptible to 
the glycopeptides with MICs of 1.0j..lglml for vancomycin and O.Sj..lg/ml for teicoplanin. 
Ampicillin, penicillin and imipenem plus vancomycin or teicoplanin failed to show synergism 
against this isolate. An indifferent phenomenon was observed. 
For these E.faecium strains displaying high-level aminoglycoside and beta-Iactam resistance, a 
trend towards an additive interaction was observed. Thus the glycopeptides plus increased 
dosages of the beta-Iactam antibiotics or imipenem has little to offer against these emergent 
nosocomial pathogens. 
The increasing numbers of enterococcal strains displaying high-level resistance to antibiotics used 
as standard therapies for serious infections as well as the absence of synergistic activity with 
combinations of these antimicrobial agents is very disturbing. 
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New bactericidal antibiotics or combinations of antibiotics are needed to treat serious 
enterococcal infections that display multiple antibiotic resistance especially among the Ejaecium 
strains. 
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5.6 PULSED-FIELD GEL ELECTROPHORESIS 
The availability of reliable molecular strain typing methods such as PFGE may be a critical factor 
in determining the success of an epidemiologic investigation (1). PFGE may also be used to 
identify related isolates which are selected for their common resistance patterns. 
Since isolates from this study were not from an outbreak, it was therefore not meant to analyse 
epidemiological observations but to determine the genetic profile between the different high-level 
aminog1ycoside resistance patterns of a selected number of Efaecalis and Efaecium strains. 
For analytic purposes, restriction fragment analysis of genomic DNA using PFGE are regarded as 
genetically related if they are undistinguishab1e (identical) from each other or are so similar that 
they are presumed to be derived from a common source. These isolates have restriction 
endonuclease digestion patterns that have the same number of bands and the corresponding bands 
have the same apparent size (1) 
An isolate is considered to be closely related to an outbreak or resistant strain if its PFGE pattern 
differs only by changes consistent with a single genetic event which may be a point mutation 
whereby a change in the PFGE pattern shows a lack of one fragment present in an outbreak or 
resistant pattern and have 2 new smaller fragments approximately the size of the larger fragment. 
Such changes typically result in 2 or 3 band differences (1). 
Point mutations may also result in the loss of a restriction site whereby the altered pattern would 
have a new larger fragment and would lose 2 smaller fragments (1). 
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Insertion of DNA into an existing restriction fragment results in isolates that are closely related 
with the genetic pattern showing a lack of one small fragment and a new fragment of a ll:\fger size 
(1). 
Deletion of DNA from a fragment shows a new fragment of a smaller size and loss of a larger 
fragment also indicating closely related strains to an outbreak or isolates that have common 
resistant patterns (1) . 
Isolates are considered to be possibly related if its PFGE pattern differs by changes consistent 
with 2 independent genetic events ie. 4 to 6 band differences as compared to an outbreak isolate 
or an isolate with a particular resistant pattern (1). 
If the restriction endonuclease pattern differ by changes consistent with 3 or more independant 
genetic events, generally 7 or more band differences, these isolates are considered genetically 
unrelated (1) . 
A situation that can make interpretation of chromosomal DNA patterns difficult and in some 
instances unknown is how to interpret small differences (79). 
The genetic study showed that there was considerable restriction endonuclease fragment 
differences among the isolates tested with similar and different resistance patterns. Fragment sizes 
ranged from :0; 48.5 to 532.5 kilobases. 
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The genomic profile of the 3 Efaecalis isolates displaying high-level amino glycoside resistance 
and susceptible to penicillin and ampicillin, showed a large band of 484.0 kilobases. These isolates 
could possibly be related because there was a difference of between 4 to 6 bands. 
The 2 Efaecalis isolates showing high-level gentamicin resistance with ampicillin and penicillin 
being susceptible were genetically unrelated. There was a difference of about 7 to 8 bands 
between these 2 strains. 
The restriction endonuclease digestion pattern of the 2 streptomycin high-level resistance 
Efaecalis strains that were susceptible to the beta-Iactam antibiotics, also showed an unrelated 
genetic profile. There was at least a difference of 7 bands. 
The one Efaecium isolate that displayed high-level resistance to both the aminoglycosides as well 
as ampicillin and penicillin showed a large fragment of 532.5 kilobases and did not resemble the 
Efaecalis strains that were highly resistant to gentamicin and streptomycin. 
The chromosomal digestion patterns of the 3 Efaecium isolates that displayed high-level 
streptomycin resistance and was susceptible to ampicillin and penicillin could possibly be 
genetically related. There was a difference of at least 5 to 6 fragments. 
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From the PFGE results it is concluded that none ofthe Efaecalis or Efaecium isolates were 
either similar or closely related therefore it can be presumed that the genetic elements leading to 
resistance occurred independently. It also suggests that PFGE analysis of enterococcal isolates 





The API 20 Strep system using either the analytical profile index or the computer API profile 
recognition program can accurately identify the commonly isolated enterococci ie. Efaecalis and 
Efaecium. Eraffinosus was mis-identified as Efaecalis and Ecasseliflavus as Efaecium. Thus 
this system cannot be relied on to accurately identify uncommon enterococci. 
The scheme described by Facklam and Collins enables microbiologists to identify accurately most 
Enterococcus species with a minimum number of conventional tests for phenotypic characteristics. 
F or appropriate management of serious enterococcal infections, the identification to species level 
is important since enterococcal species such as Efaecium and Ecasseliflavus are resistant to a 
range of antimicrobial agents and express high-level resistance to penicillin and ampicillin (MIC 
> 128.0,uglmI). 
The use of an inoculum < 1 07 _108 CFU s/mI for susceptibility testing of enterococci results in false 
susceptibility to penicillin and ampicillin. It is therefore recommended that beta-Iactamase testing 
be performed on all serious enterococcal infections since a false susceptibility report can result in 
the patient being treated inappropriately with ampicillin with devastating consequences for the 
patient. 
With the high percent of false susceptibility for aminoglycosides and cephalosporins reported with 
blood enriched media, prompted the testing of aminoglycosides and cephalosporins. 
On average 55% of the isolates showed false susceptibility to gentamicin and 35% to tobramycin 
and netilmicin with media supplemented with blood. 
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The only cephalosporins affected was cefotaxime and cefuroxime with a false susceptibility of 
28% and 17% respectively. These antibiotics were the same as described by others to be affected 
by blood enriched media. 
False susceptibility for the aminoglycosides was not as high as described by others. The reason for 
this might be that all the isolates that showed a few colonies around the zone of inhibition were 
interpreted as resistant on blood enriched susceptibility agar plates. 
All laboratories should be aware that false susceptibility for enterococcal isolates does occur for 
gentamicin, tobramycin, netilmicin, cefotaxime and cefuroxime when media supplemented with 
blood are used. 
Information regarding the mechanism through which the discrepancy in susceptibility testing of 
gentamicin, tobramycin, cefotaxime and cefuroxime occurs would facilitate the formulation of 
new types of media or more accurate and reliable in-vitro methods for testing these antibiotics 
with enterococci. 
For now media such as Mueller-Hinton agar without the addition of blood should be used to test 
aminoglycosides and cephalosporins for enterococcal isolates, since these organisms grows well in 
this media. 
Tests for the detection of high-level gentamicin resistance, which precludes bactericidal synergy 
with clinically achievable ooncentrations of the antibiotic, make time consuming and labour-
intensive synergy tests such as time-kill studies and checker-board titrations unnecessary. 
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The high frequency of high-level resistance to gentamicin (26.2%) and streptomycin (31.8%) as 
shown from the study is a matter of concern. The alternative treatment regimens for infection with 
such strains are limited to single therapy with one of the glycopeptides. 
Thus screening of enterococci for high-level aminoglycoside resistance is an essential test for 
management of patients with serious enterococcal infections such as bacterial endocarditis. 
The high content disc, broth or agar plate (with a concentration of 500 or 2000,ug/ml of 
gentamicin) and the Etest methods appear highly reliable for the detection of such resistance to 
gentamicin. Anyone of these methods may be used depending on the facilities available in the 
laboratory. 
The study of synergism which is determined by the killing rate or the establishment of a killing 
curve have become redundant and can be replaced for high-level organism resistance. 
On the basis of studies presented, it appears that Efaecalis strains that demonstrate intrinsic low-
level gentamicin resistance (MIC ~ 500,ug/ml) and are susceptible to penicillin and ampicillin 
(MIC ~ 1. O,ug/ml) show a synergistic effect between the beta-Iactams and gentamicin. This still 
represent the optimal therapy for severe enterococcal infections. 
In the presence of high-level resistance to gentamicin (MIC 22000,ug/ml) Efaecalis isolates that 
were susceptible to ampicillin and penicillin (MICs of ~ 1. O,ug/ml), the combination of penicillin 
plus vancomycin or teicoplanin, ampicillin plus vancomycin or teicoplanin displayed synergism. 
These combinations might be successful for the treatment of high-level aminoglycoside resistant 
strains of enterococci. 
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In the E.faecium strains that displayed high-level gentamicin resistance with MICs of 128.0 or 
256f.lglml for penicillin and 64 or 128f.lglml for ampicillin; synergism was not observed, although 
an increased concentration of beta-l act am antibiotic was used. 
Vancomycin and teicoplanin are bactericidal antibiotics. These antimicrobial agents inhibit cell 
wall synthesis and are able to kill susceptible micro-organisms. In general bactericidal 
antimicrobial agents produce MBCs within 2 two-fold dilutions ie. 4 times the MIC. With 
E.faecalis and Eraffinosus the MBCs for the glycopeptides were 3-4 two-fold dilutions ie. 8-16 
times greater than the MIC for E.faecalis and Eraffinosus. This indicates a bacteriostatic effect 
for the glycopeptides at a concentration obtained in-vivo. 
E.faecium and Ecasseliflavus displayed tolerance which is when the MBC:MIC ratio is ~ 32 after 
24 hours of incubation. Tolerance renders a normally bactericidal agent bacteriostatic. Although 
vancomycin and teicoplanin display bacteriostatic effect for E.faecalis and E raffinosus and a 
tolerant effect for E.faecium and Ecasseliflavus , these antimicrobial agents have a very good 
therapeutic effect against such organisms. 
In view of reports of vancomycin resistant strains in various parts of the world, the universal 
susceptibility of enterococci to vancomycin no longer exists. 
Routine susceptibility testing of this antibiotic is thus a necessity for clinically relevant 
enterococcal isolates. 
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All isolates tested for vancomycin are susceptible at this stage. It is vitally important that 
laboratories perform beta-lactamase tests to accurately identify penicillin and especially ampicillin 
resistance. 
Use of molecular strain typing such as pulsed-field gel electrophoresis (pFGE) has now become a 
standard practice in hospital infection control to evaluate the epidemiology of nosocomial 
infections. PFGE is one of the most widely used tools for investigating bacterial outbreaks and for 
studying of relationships between multi-resistance or high-level resistance of bacteria. It provides 
information on genetic relations between isolates. Our study by means of pulsed-field gel 
electrophoresis (PFGE) of Ejaecalis and Ejaecium with high-level resistance to gentamicin and / 
or streptomycin showed that the isolates with the same susceptibility patterns had different 
restriction endonuclease patterns. That is, there was no evidence of a common origin of these 
isolates. 
Thirteen percent of the enterococcal isolates showed high-level resistance (MIC 256flg/ml) to 
penicillin, ampicillin and imipenem. Nine (8.4%) were Ejaecium and 5 (4.7%) were 
E.casseliflavus and none were Ejaecalis. Ten (9.3%) of these isolates displayed high-level 
aminoglycoside resistance. Seven (6.5%) showed high-level resistance to gentamicin and 
streptomycin, 2 (1.9%) to streptomycin only and 1 isolate to gentamicin only. All 4 (3.7%) of the 
E.casseliflavus strains showed high-level resistance to both the aminoglycosides. Of the 6 (5.6%) 
Ejaecium strains, 4 displayed high-level resistance to gentamicin and streptomycin, 1 isolate was 
only resistant to gentamicin and the other to streptomycin only. 
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There are no alternatives to treat enterococcal infections if the organism displays high-level 
aminoglycoside resistance, is resistant to the penicillins as well as the glycopeptides. There is a 
strong need for research, to leap ahead in order to understand the mechanism of how enterococci 
seem to acquire multiple resistance to antibiotics at such an alarming rate. In the meantime, the 
only alternative for high-level resistance to penicillin, ampicillin and vancomycin resistance 
especially for the Efaecium strain seems to be teicoplanin or daptomycin. 
From these observations the following recommendations can be made for susceptibility testing of 
enterococci. For the aminoglycosides and cephalosporins susceptibility testing should be 
performed on media without the addition of blood. Screening for high-level resistance to 
gentamicin can be determined by the disc agar or Etest method that seem to be highly reliable. 
Beta-Iactamase tests should be performed routinely for all enterococcal isolates. 
The unbounded promise of the glycopeptides for therapy of multi-resistant enterococci is being 
threatened as seen in other countries. Considering what the Enterococcus has done in the 1990's, 
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APPENDICES 
SECTION A : IDENTIFICATION OF ENTEROCOCCI 
API Identification 
(i) A dense suspension with a turbidity of greater than a 4 McFarland standard was made 
from a pure culture of the test organism in 2m1s of sterile distilled H20. 
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( ii ) Approximately 150 tLl of this suspension was used to rehydrate and inoculate the enzymatic 
substrates (pyruvate) Voges-Proskauer (VP) to L-leucine-2-naphthyl-amide (LAP). 
( iii ) The tube portion only was filled (ie. Yz way) for the arginine (ADH) test. 
The metabolic end products produced during the period of incubation were revealed through 
indicator change or by the addition of reagents. 
The fermentation tests comprises the second half of the strip. 
(iv) Tests ribose (RIB) to glycogen (GLYG) were inoculated with an enriched medium to which 
approximately 0.5m1s of the test suspension was added. This reconstitutes the sugar substrates. 
(v) The cupules of the tests arginine (ADH) to glycogen (GLYG) were overlayed with mineral 
oil to create an anaerobic atmosphere. 
Fermentation of carbohydrates was detected by a shift in the pH indicator. 
( vi ) Inoculated API strips were incubated at 35 - 37 0 C for 4 hours to obtain a first reading and if 
necessary, 24 hours to obtain a second reading. 
( vii) After the incubation period, the following reagents were added : 
Voges-Proskauer test (VP) : 1 drop VPI and VP2. 
Hippurate Test (HIP) : 2 drops Ninhydrin solution (Nin) 
Pyrrolidonyl-2-naphthylamide (PYRA), 6-Bromo-2-naphthyl-a-D-galactopyranoside 
(a-Gal) , Naphthol AS-BI P-D-gluconate (P-Gur), 2-naphthyl-p-D-galactopyranoside (p-Gal), 2-
naphthylphosphate (Pal), L-Ieucine-2-naphthylamide (Lap) Tests : 1 drop ZYM A 
andZYMB. 
After 10 minutes, reactions were read by referring to the colour chart or interpretation table. 
Results were recorded on a report sheet. 
( viii) Identification of the organism was obtained by using the API 20 Strip Analytical Profile 
Index. 
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( ix ) On the report sheet, tests are separated into groups of 3 and a number 1,2,4 is indicated for 
each group. 
( x ) By adding the numbers corresponding to only the positive reactions within each group, 7 
digits are obtained which constitute the profile number. 
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Fig. 18 Identification of enterococci using the API 20 strip analytical profile index 
Salt tolerance test 
Broth test 
Procedure 
Identification by conventional biochemical tests 
(i) Inoculate 2 to 3 colonies of test culture into 6.5% NaCI broth. 
(ii) Incubate culture at 35-3rC aerobically overnight. 
Result: Examine culture for evidence of growth (indicated by turbidity) after 24- 48 hours. 
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Positive reaction: Growth in the medium within 24-48 hours indicated the strain was salt tolerant. 
Negative reaction : No growth in 6.5% NaCl broth .. 
Controls : 
Agar plate test 
Procedure 
Positive control: E.faecalis ATCC 29212 
Negative control : S. bovis (ATCC 33317) 
(i) 2 to 3 colonies of test culture was inoculated onto 6,5% NaCI agar plate. 




(iii) Agar plate was examined for the presence of bacterial growth. 
Positive reaction : Visible growth seen on the agar surface. 
Negative reaction : No growth visible after 24-48 hours incubation. 
Controls : Positive control : E.faecalis ATCC 29212 
Negative control : S. bovis (ATCC 33317) 
Bile aesculin test 
Agar plate method 
Procedure 
(i) Inoculated 40% bile aesculin medium with 2 to 3 colonies of the test organism. 
(ii) Agar plate was incubated at 35-37°C overnight aerobically. 
(iii) Plates were examined for evidence of growth and blackening of the medium (aesculin 
hydrolysis) . 
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Positive reaction : Growth on the agar surface with diffuse blackening of the medium after 24-48 
hours of incubation. 
Negative reaction : No growth or growth without blackening of the medium. 
Controls: Positive control: E.faecalis ATCC 29212 
Negative control: s.mutans ATCC 35668 
Arginine deamination 
Procedure 
(i) A single colony of the test isolate was inoculated into 5rnls of brain-heart infusion broth. 
(ii) Incubated inoculated broth at 35-37°C overnight. 
(iii) Arginine was inoculated with 1 to 2 drops of the inoculated brain-heart infusion broth. A 
layer of sterile mineral oil was added to the broth. 
(iv) Tests were incubated at 35-37 D C for 48 hours. 
(v) Broths were observed for a change in colour. 
Positive reaction: Violet to deep purple colour. 
Negative reaction: No change in colour of the broth (yellow). 
Controls: Positive control : Ejaecalis ATCC 29212 




(i) Pyruvate medium was inoculated with 1 to 2 drops of overnight incubated brain-heart infusion 
broth with the test organism. 
(ii) Incubated inoculated pyruvate medium at 35-3rC for 24-48 hours. 
(iii) Tests were observed for a change in colour. 
Positive reaction: Yellow (A yellow colour with only a hint of green in interpreted as positive). 
Negative reaction: Green or greenish yellow. 
Controls: Positive control : E. faecalis ATCC 29212 
Negative control : s.mutans ATCC 35668 
Tellurite tolerance 
Procedure 
(i) 2 to 3 colonies of the test organism were inoculated directly onto the medium. 
(ii) Inoculated plates were incubated at 35-37°C for 24-48 hours. 
(iii) Plates were examined for the presence of black colonies. 
Positive reaction: Black colonies on the medium usually after 24-48 hours. 
Negative reaction: No growth or growth without blackening of colonies. 
Controls: Positive control: E.faecalis ATCC 29212 
Negative control: E.faecium ATCC 35667 
Hippurate hydrolysis 
Procedure 
(i) Inoculated 2 to 3 colonies of the test isolates into O. 5mls of sodium hippurate broth. 
(ii) Tests were incubated at 35-37°C for 2 hours. 
(iii) 2 drops of ninhydrin was added. Mix well. 
(iv) Tests were reincubated for 10 minutes at room temperature. 
(v) Examined for the development of the purple colour. 
Positive reaction: Purple colour within 10 minutes after addition of ninhydrin. 
Negative reaction: Colourless to pale yellow colour broth. 
Controls: Positive control: S.agaiactiae (ATCC 13813) 




(i) Inoculated starch agar with 2 to 3 colonies of the test organism. 
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(ii) Culture plates were incubated at 35-37°C aerobically for 48 hours. When the organisms were 
grown well, the surface of the agar plate was flooded with 0.5mls of Gram's iodine. 
Positive reaction: Complete clearing around the organisms indicates hydrolysis of starch. A 
partially cleared area surrounding the growth indicates partial hydrolysis and was interpreted as a 
weak positive reaction. 
Negative reaction: If the plate stained uniformly dark purple because of the reaction of the iodine 
and starch, a negative reaction was recorded. 
Controls: Positive control: S.bovis (ATCC 33317) 
Negative control: E.faecalis ATCC 29212. 
Voges-Proskauer (VP) test (Coblentz) 
Procedure 
(i) Inoculated VP broth with an inoculum standardized to a turbidity of a McFarland number 4 
standard from an overnight culture plate to be tested. 
(ii) Incubated medium at 30 ° C for 6 to 7 hours. 
(iii) 0.6mls of ex-naphthol, followed by O.2ml of 40% KOH containing 0.3% creatine was added. 
(iv) Tubes were shaken vigorously for 30 seconds to 1 minute. 
(v) To determine a colour change, broths were read within 15 minutes. 
Positive reaction: Pink or red colour at the surface of the broth. 
(Strong positive resulted in a diffusion of a deep red colour throughout the broth. Faint pink 
around the surface edge was a weak positive reaction). 
Most positive reactions wee apparent within 15 minutes. 
Final results were read after 1 hour. 
Negative reaction: No colour development (colourless) 
Controls: Positive control : E.faecalisATCC 29212 
Negative control : E. coli ATCC 25922 
Carbohydrate fermentation tests (1 %) 
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The following carbohydrates were tested : mannitol, sorbose, sorbitol, inulin, arabinose, melibiose, 
sucrose, trehalose, lactose, glycerol, salicin, maltose, raffinose, glucose. 
Inoculation of carbohydrates 
(i) A single colony of the test isolate was inoculated into 5mls of brain-heart infusion broth. 
(ii) Incubated inoculated broths at 35-37°C overnight. 
(iii) All the carbohydrate media were inoculated with 1 to 2 drops of the inoculated brain-heart 
infusion broth culture. 
(iv) Tests were incubated at 35-37°C and read after 24-48 hours. 
(v) Broths were observed for a colour change. 
Positive reaction : Yellow. 
Negative reaction : Purple (no change in colour). 
Controls: Positive control : Ejaecalis ATCC 29212 
Negative control : E.faecium ATCC 35667 
Test or growth at 100C and 45 °C 
Procedure 
(i) A single colony of the test organism was inoculated into brain-heart infusion broth. 
(ii) Inoculated broth was incubated at 35-37 °C overnight. 
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(iii) A drop of the overnight broth culture was placed into 5m1s sterile BHI broth and incubated at 
the respective temperatures ie. 10 and 45 °C for 24 hours. 
(For the loot incubator, a refrigerator was adjusted to a temperature of 10°C). 
(iv) Broths were examined for the presence of bacterial growth by plating out a loopful of the test 
\ 
organism onto a blood agar plate. 
Positive reaction: Presence of growth of the organism on the agar plate at both temperatures (10 
and 45°C). 
Negative reaction: No growth of the test organism at both the above mentioned temperatures. 
Controls: Positive control: E.faecalis ATCC 29212 
Negative control: s.mutans ATCC 35668 
Survival at 60°C for 30 minutes 
Procedure 
(i) Organism to be tested was picked up into duplicate 0.5 ml volumes of brain-heart infusion 
broth. 
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(ii) 1 tube containing the test organism was incubated in a waterbath at 60°C for 30 minutes and 
the control tube was left unincubat~d. 
(iii) After 30 minutes, both the tubes ie. the incubated and the unincubated were plated out onto 
blood agar plates and incubated at 35-3rC for 24 hours. 
(iv) After overnight incubation, both the plates were examined for the presence of growth. 
Positive reaction: Bacterial growth on the test and the control agar plate. 
Negative reaction: No growth on the agar plate incubated at 60°C for 30 minutes. Growth on the 
unincubated agar plate (control). 
Controls: Positive control: E. faecalis ATCC 29212 
Negative control: s.mutans ATCC 35668 
Type of haemolysis 
Procedure 
(i) A single colony of the test organism was plated out onto a blood agar plate and the agar was 
stabbed with the inoculating loop to test for haemolysis. 
(ii) Inoculated plates were incubated at 35-3rC for 24 hours in an atmosphere of 
5-10% CO2. 
(iii) After overnight incubation the blood agar plates were examined for the type of haemolysis 
present, ie. the destruction of erythrocytes around the stab in the agar. 
Results 
If destruction of some but not all of the erythrocytes is apparent, the haemolytic reaction was 
recorded as alpha. 
If destruction of all of the erythrocytes occurs, the haemolytic reaction was recorded as beta. 
If no destruction of cells is apparent, this indicated a non-haemolytic reaction. 
Motility 
Procedure 
(i) The medium was inoculated from an overnight incubated broth with an inoculating straight 
WIre. 
(ii) The straight wire was inserted into the centre of the medium in the tube (± 2.5 cm). 
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(iii) The inoculated tube was placed in a 30 D C incubator (since some strains become non-motile at 
3rC but are motile from temperatures between 25 and 30 D C ). 
Results 
Motile strains grow outward to the edge of the tube and downward towards the bottom of the 
tube. 
Motility medium was incubated for 24-48 hours until good growth was observed. 
Non motile strains grew on the line of inoculum only. 
Controls : Positive control : E. gallinarium (Lab control strain) 
Negative control: E. faecalis ATCC 29212 
Detection ofL-pyrrolydonylpeptidase (PYR) 
Procedure 
(i) PYR disc was moistened with 1O,u1 distilled water. 
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(ii) With a sterile loop, about 10 colonies of the test organism from an overnight culture plate was 
smeared gently in the centre of the moistened disc. 
(iii) After inoculation, test was incubated at room temperature for 2 minutes. 
(iv) A drop of colour developer was dispensed onto the test area of the disc and observed for the 
development of a pink colour. 
(v) Results were read after 1 minute. 
Positive reaction: Inoculated portion of disc turned bright pink, orange-pink or cherry red within 
10 seconds to 1 minute after applying the colour developer. 
Negative reaction: No colour change. Reactions after 1 minute is considered negative. 
Controls: Positive control: E. faecalis ATCC 29212 
Negative control : s.mutans ATCC 35668 
Determination of Lancefield group antigen 
Procedure 
(i) 4-5 colonies of test organism were picked up into a tube containing O.4mls of extract enzyme. 
(ii) Suspension was incubated at 35-3rC for 30 minutes. 
(Ui) The group D latex suspension was resuspended by shaking vigorously for a few seconds. 
(iv) Using a sterile Pasteur-pipette, 1 drop of extract was placed on a circle on the Reaction Card. 
(v) 1 drop (20f.l-l) of group D latex suspension was added next to the extract on the Reaction 
Card. 
(vi) The contents in the circle was mixed with a mixing stick and spread gently to cover the 
complete area of the circle. 
(vii) The card was rocked gently for about 1 minute. 
(viii) Test was observed for the presence of agglutination. 
Positive reaction :Agglutination showing clearly visible clumping of the latex particle 
Negative reaction : Milky appearance of the latex particles. 
Controls: Positive control : Efaecalis ATCC 29212 
Negative control: s.mutans ATCC 35668 
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Procedure 
SECTION B : TEST FOR BETA-LACTAMASE PRODUCTION 
Chromogenic Cephalosporin Method 
(i) 5/l1 ofnitrocefin was dotted onto a Whatman 3l\1M filter paper. 
(ii) 2-3 colonies of the test organism was smeared onto the filter paper using a mixing stick 
(iii) Filter paper was observed for a colour change. 
Positive reaction: Dark pink to red. 
Positive reactions usually appear within 15 seconds to 5 minutes. 
Negative reaction: No colour change (remains yellow) 
Controls: Positive control: S.aureus NCTC 11561 (Beta-Iactamase producing). 
Negative control : s'aureus NCTC 6571 (Non beta-Iactamase producing). 
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SECTION C : ANTIMICROBIAL SUSCEPTmILITY TESTING 
8.3.1 Disc diffu~ion susceptibility testing 
8.3 . 1.1 Modified "Stokes" method 
Media 
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Mueller-Hinton ae;ar plus 5% lysed horse blood. In addition Mueller-Hinton agar only was used 
for testing aminoglycosides and the cephalosporins. 
Procedure 
Preparation of inoculum 
A suspension of the inoculum was made by touching 4 to 5 colonies and emulsifYing it in 10mls of 
sterile distilled H20 . 
The inoculum gave semi-confluent growth of the colonies on the plate after overnight incubation. 
Inoculations 
Using the rotary plate method, control strain (S.aureus NCTC 6571) was inoculated to the centre 
of the plate by means of using a sterile cotton wool swab leaving an uninoculated band of 1.5cm 
around the edge of the plate. The test organism was seeded evenly to the 1. 5cm band using a 
sterile swab immersed in the suspension containing the test isolate. 
There was fl central band of 3 to 4 mm left uninoculated between the test and control organisms. 
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Antibiotic discs 
Discs were applied with forceps on the uninoculated band between the test and control organisms. 
Discs were gently pressed onto the agar surface to ensure even contact with the medium. 
Incubation 
Test and control organisms were incubated at 35-37°C for 16-18 hours in an atmosphere of5-
10% CO2. 
Reading of zones of inhibition 
If the test zones are obviously larger than or equal to the control, it was not necessary to perform 
any measurements. If there was any doubt, zones were measured with calipers. 
Zones were measured from the edge of disc to the edge of the zone. 
Interpretation 
Susceptible : Zone size equal to, wider than, or not more than 3mm smaller than the 
control. 
Intermediate : Zone size greater than 3mm, but smaller than the control by more than 
3mm. 
Resistant : Zone size 3mm or less. 
Kirby-Bauer method 
Media 
Mueller-Hinton agar supplemented with 5% lysed horse blood. 
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Mueller-Hinton agar only was used for testing the aminoglycosides and the cephalosporins as an 
additional medium to compare the results of these antibiotics on agar plates with and without the 
addition of blood. 
Procedure 
Preparation of inoculum 
At least 4 to 5 morphologically similar colonies of the test organisms were touched with a wire 
loop and transferred to a tube containing 5ml of sterile tryptic soy broth . 
Inoculated tubes were incubated for 2 to 5 hours at 35 0 C to produce a bacterial suspension of 
moderate turbidity. Inoculum was standardized to match the turbidity of a 0.5 McFarland standard 
(approximately 108 CFU/ml) by diluting the inoculum with sterile broth. 
Inoculation 
Plates were inoculated within 15 minutes of preparation of the standardized suspension so that the 
density of the inoculum remained the same. For the inoculation of the medium, a sterile cotton-
wool swab was dipped into the suspension and the surplus removed by rotation of the swab 
against the side of the tube above the fluid level. The medium is inoculated by even streaking of 
the swab over the entire sterile surface in 3 directions. The plate was rotated at 60 0 each time to 
ensure even distribution of inoculum. This resulted in uniformly circular inhibition zones and a 
confluent lawn of growth. 
Antibiotic discs 
After the inoculum was dried, drug impregnated discs were applied with forceps. 
Discs were gently pressed onto the agar surface to ensure complete contact. 
Incubation 
Plates are incubated 16-18 hours at 35-37°C in an atmosphere of5-10% CO2. 
Reading of zones of inhibition 
185 
Diameters of the zones of complete inhibition (as judged by the unaided eye) were measured, 
including the diameter of the disc, using calipers. The endpoint was taken as the area showing no 
obvious, visible growth. 
Interpretation 
Each zone size of inhibition was interpreted by referring to a ref~rence table. ( zone diameter 
interpretation standard- NCCLS Document MlOO -Ss). 
Organisms were reported as either susceptible, moderately susceptible or resistant. 
Controls 
S. aureus ATCC 25923 was tested with each batch of test organisms against all the antibiotics 
tested and the results recorded. 
The control results are compared to the NCCLS control limit table for monitoring antimicrobial 
disc susceptibility tests zone diameter(mm) limits 
(NCCLS Document MlOO -Ss). 
Disc diffusion susceptibility test results 
Table XXV Analysis of Kirby-Bauer susceptibility test results according to NCCLS zone 
diameter interpretation standards (107 isolates tested) 
ANTIBIOTIC CONe. S 
Penicillin 10units nil 
Ampicillin lOj.{g nil 
Tetracycline 30j.{g 43(40%) 
Chloramphenicol 30j.{g 75(70%) 
Cotrimoxazole lOj.{g 9(8.4%) 
Clindamycin 24j.{g nil 
Rifampicin 5j.{g 20(18.7%) 
lmipenem 10j.{g 92(86%) 
Piperacillin 75j.{g 85(79.4%) 
Ciprofloxacin 5j.{g nil 
Vancomycin 30j.{g nil 
T eicoplanin 30j.{g 107(100%) 
S : Susceptible 
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Table XXVI Analysis of Stokes susceptibility test results according to the criteria set out 
by the Journal of Antimicrobial Chemotherapy (JAC) [107 isolates tested] 
ANTIDIOTIC CONe. S I R 
Penicillin 1,ug nil 22(20.6%) 85(79.4%) 
Ampicillin lO,ug nil 93(87%) 14(13 .1%) 
Tetracycline 10,ug 11(10.3%) 34(31.8%) 62(57.9%) 
Erythromycin 5,ug 16(14.9%) 33(30.8%) 58(54.2%) 
Chloramphenicol 10,ug 19(17.8%) 48(44.8%) 40(37.4%) 
Cotrimoxazole 25,ug 23(21.5%) 55(51.4%) 29(27.1%) 
Clindamycin 2,ug nil 2(1.9%) 105(98.1%) 
Rifampicin 5,ug nil 65(60.7%) 42(39.3%) 
lmipenem 10,ug nil 93(86.9%) 14(13 .%) 
Piperacillin 75,ug nil 93(86.9%) 14(13 .1%) 
Ciprofloxacin 5,ug nil 73(68.2%) 34(31.8%) 
Fusidic acid 2,ug 7(6.5%) 83(77.6%) 17(15.8%) 
Vancomycin 30,ug 107(100%) nil nil 
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SECTION D : MINIMUM INHIBITORY CONCENTRATION (MIC) 
Agar dilution procedure 
The antimicrobial agent was incorporated into the agar medium, with each plate containing a 
different concentration of the antibiotic. 
The inocula was applied to the agar surface using an inoculum replicating apparatus. 
Media 
Mueller-Hinton agar supplemented with 5% lysed horse blood. 
An additional medium ie. Mueller-Hinton agar without blood was used for testing of the 
aminoglycosides am;! cephalosporins. 
Preparation of agar plates 
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(i) A two-fold doubling dilution of antimicrobial solutions (final concentration of 512-0.03,uglml) 
was added to molten test agar that was allowed to equilibrate in a water bath at 50 °C. 
(ii) The agar and antimicrobial solution was thoroughly mixed and the mixture was poured into 
petri dishes on a level surface. 
(iii) Plates were poured as quickly as possible after mixing to prevent cooling and partial 
solidification in the mixing bottle (agar depth was between 3 and 4 mm). 
(iv) The agar was allowed to solidifY at room temperature. 
Appropriate reference control strains were tested with each batch of tests performed. 
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Quality control 
Reference strain S. aureus ATCC 29213 was used as a control organism. The control organism 
was inoculated onto the agar medium incorporating the antimicrobial agents, containing a 
different concentration of the antibiotic. The reference strain results were compared to the 
NCCLS Document MlOO -Ss table of acceptable quality control ranges of minimum inhibitory 
concentration (MIC). 
Control plates 
Drug free control plates with and without supplements were prepared. 
Preparation of inoculum 
(i) Inoculum was prepared by touching the top of the at least four or five colonies 
morphologically similar and inoculating them into a tube containing 5.0ml of Mu ell er-Hint on 
broth. 
Incubated the bacterial suspension for 2-5 hours at 35-3rC until it was visibly turbid. 
Density of the broth culture was adjusted to a turbidity equivalent to a 0.5 McFarland standard by 
adding sterile broth. 
(ii) Cultures adjusted to this standard contained approximately 1 08CFU s/ml. Adequate light 
source was essential for the adjustment of the turbidity of the inoculum. The adjusted suspension 
was diluted 1: lOin sterile broth to obtain the desired inoculum concentration of 107 CFU/ml. 
The inoculum replicator deposited approximately 1 to 2,u1 on the agar surface. The final inoculum 
on the agar area was approximately 104CFUs in an agar area whose diameter is 5 to 8mm. 
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Inoculating agar plates 
(i) The surface of the agar medium was dried before inoculating it. Plates were placed with the 
lids ajar in a 35-3rC incubator for about 30 minutes. 400111 of each suspension was placed into 
the corresponding well in the replicator seed block. Well 37 was used as a marker. 
A known control strain was added with each batch of tests. 
(ii) 1 to 2111 of each inoculum was applied to the agar surface with an inocula-replicating device. 
(iii) Inoculated a control plate (no antibiotic present) first and then, starting with the lowest 
concentration, plates containing the different antibiotic concentrations. A second control plate was 
inoculated last to ensure that there was no contamination or antimicrobial carry over during the 
inoculation process. 
Incubation 
(i) Inoculated plates were allowed to stand at room temperature until the moisture in the inoculum 
spots were absorbed onto the agar surface, ie. until the spots were dry. 
The plates were inverted and incubated for 16-20 hours at a temperature of35-3rC in an 
atmosphere of5-10% CO2, 
Determining endpoints 
(i) Plates were laid on a dark non-reflecting surface and the results read. A plate reader with a 
light was used. 
MIC was recorded as the lowest concentration of antimicrobial-agents that completely inhibited 
growth. 
(ii) Sub cultured to check purity of culture. 
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Broth microdilution procedure 
Media 
(i) SO/1-1 of Mu ell er-Hint on broth supplemented with 2Smg ofCa2+ and 12.Smg Mi+/l was added 
from wells 2-11. 
(u) SO/1-1 of the antimicrobial agent was added to wells 1 and 2. 
Starting concentration of antibiotic was SI2/1-g/ml. 
(ui) 50/1-1 of suspension (antibiotic plus broth) from well 2 was transferred to well 3 . 
(iv) Continued double diluting until well 11 . 
Discarded 50/1-1 of suspension from well 1l. 
Inoculum 
(i) Inoculum was standardized to match a O.S McFarland standard (approximately 108CFUs/ml). 
Inoculum was further diluted 1: 10 to yield a final inoculum of 107CFUs/ml. SOj,{1 of this 
suspension was inoculated into all wells (ie. 1-12). 
The final concentration of bacteria was approximately Sx l050r Sxl04CFUs/well. 
After addition of inoculum the final starting concentration of antimicrobial agent was 2S6/1-glml. 
Incubation 
(i) Microtitre trays were covered with a plastic cover to prevent drying and incubated at 3S-3rC 
for 16-20 hours in ambient air. 
Interpretation of results 
(i) MIC was recorded as the lowest concentration of antimicrobial agent that completely inhibits 
growth of the organism as detected by the unaided eye. 
Quality control 
(i) Amount of groWth in the wells containing the antibiotic was compared to the amount of 
growth in the growth control well (ie. well 12). 
(ii) Quality control strain ATCC 29212 was set up with each batch of tests. (MIC result is only 
valid if the Q.c. reference strain falls within the NCCLS acceptable Q.c. range) . 
A row of sterility broth control was set up with each batch of tests. 
This uninoculated broth must be free of any growth. 
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Table XXVII Minimum inhibitory concentration (MIC) results of the beta-Iactam and 
glycopeptides 
MIC PENICILLIN AMPICILLIN IMIPENEM VANCOMYCIN TEICOPLANIN 
(ug/ml) 
0.25 5(4.7%) 8(7.5%) 6(5.6%) nil 20(18.7%) 
0.5 17(15.9%) 75(70.1%) 29(27%) 19(17.7) 65(60.7%) 
1.0 62(59.9%) 10(9.3%) 53(49.5%) 62(57.9%) 22(20.6%) 
2.0 2(1.9%) nil 1(0.9%) 22(20.6%) nil 
4.0 7(6.5%) nil 4(3.7%) 4(3 .7%) nil 
8.0 nil nil nil nil nil 
16.0 2(1.9%) 4(3 .7%) 2(1.9%) nil nil 
32.0 nil 5(4.7%) nil nil nil 
64.0 6(5.6%) 5(4.7%) 6(5 .6%) nil nil 
128.0 4(3 .7%) nil 4(3 .7%) nil nil 
256.0 2(1.9%) nil 2(1.9%) nil nil 
512.0 nil nil nil nil nil 
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Table XXVIII Minimum inhibitory concentration (MIC) of ami~oglycosides and 
cephalosporins on Mueller-Hinton agar only 
MIC GENTA TOBRA NETIL AK CTX CEFA1\1l CEFUR 
(jig/mI) 
0.25 nil nil nil nil nil nil nil 
0.5 nil nil nil nil nil nil nil 
1.0 nil nil nil nil nil nil nil 
2.0 nil nil nil nil nil nil nil 
4.0 4 nil nil nil nil 3 1 
(3 .7%) (2.8%) (0.9%) 
8.0 26 20 23 nil 2 2 1 
(24.6%) (19.7%) (21.5%) (1.9%) (1.9%) (0.9%) 
16.0 27 30 27 nil 18 17 16 
(25.2%) (28%) (25.2%) (16.8%) (15.9%) (14.9%) 
32.0 18 15 16 20 30 27 32 
(16.8%) (14%) (14.6%) (18.7%) (28%) (25.2%) (29.9%) 
64.0 6 3 3 42 10 7 6 
(5 .6%) (2.8~) (2.8%) (39 .2%) (9.3%) (6.5%) (5.6%) 
128.0 nil 7 4 25 11 11 10 
(6.5%) (3.7%) (23.4%) (10.3%) (10.3%) (9.3%) 
256.0 nil 10 10 10 11 14 16 
(9.3%) (9.3%) (9.3%) (10.3%) (13.1%) (14.9%) 
>256.0 26 22 24 10 25 26 25 






















Table XXIX Minimum inhibitory concentration (MIC) of aminoglycosides and 
cephalosporins with Mueller-Hinton agar (MHA) supplemented with 
5% lysed horse blood and Mueller-Hinton agar only 
MIC GENTA TOBRA NETIL AK CTX CEFAM CEFUR 
(ug/ml) 
0.25 nil nil nil nil nil nil nil 
0.5 nil nil nil nil nil nil nil 
l.0 nil 6 nil nil nil nil nil 
(5 .6%) 
2.0 10 8 6 nil 10 nil 4 
(9.3%) (7.5%) (5.6%) (9.3%) (3 .7%) 
4.0 34 30 26 nil 16 2 8 
(31.8%) (28%) (24.3%) (14.9%) (1.9%) (7.5%) 
8.0 12 14 8 nil 4 3 6 
(11.2%) (13.1%) (7.5%) (3.7%) (2.8%) (5 .6%) 
16.0 11 12 14 nil nil nil nil 
(10.3%) (11.2%) (13.1%) 
32.0 9 10 15 22 15 18 10 
(8.4%) (9.3%) (14.0%) (20.6%) (14%) (16.8%) (9.3%) 
64.0 5 6 9 44 10 14 10 
(4.7%) (5 .6%) (8.4%) (41.1%) (9.3%) 
I 
(13 .1%) (9.3%) 
128.0 2 3 5 20 20 28 30 
(1.9%) (2.8%) (4.7%) (18.7%) (18 .7%) (26.2%) (28%) 
256.0 2 1 " 10 12 17 15 .) 
(1.9%) (0.9%) (2.8%) (9.3%) (11.2%) (15 .9%) (14%) 
>256.0 22 17 21 11 20 25 24 

























Comparison of MIC with and without supplemented blood for the aminoglycoside showed that 
there was a false susceptibility of 50% for gentamicin, 40% for tobramycin and 38% for netilmicin 
in blood enriched media. Amikacin was the only aminoglycoside that remained unaffected by the 
presence of5% lysed blood in the media. Cefotaxime displayed a false susceptibility of26%. 
Cefuroxime 15% , cephalothin 3% and cefamandole was unaffected. 
Table XXX MICs for vancomycin performed using the broth microdilution method to 
determine MBCs 
VANCOMYCIN 























Table XXXI MICs for teicoplanin performed using the broth microdilution method to 
determine MBCs 
TEICOPLANIN 
























Comparing the MICs ofthe agar dilution and the microtitre method, MICs were the same or one 
dilution lower with the microtitre method. MBCs were 3-4 two-fold dilutions ie. 8-16 times 
greater than the MiC. These isolates had an MBC:MIC ratio <32J.lg/ml indicating that 
vancomycin and teicoplanin are bacteriostatic for Ejaecalis and E.raffinosus. Isolates that had an 
MBC:MIC ratio z 32J.lg/ml were Ejaecium and E.casseliflavus strains indicating that these strains 
were tolerant. 
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SECTION E : MINIMUM BACTERICIDAL CONCENTRATION (MBC) 
Procedure 
(i) After the broth MIC was performed, MBC was determined. 
(ii) Contents of each well showing no visible growth was mixed to achieve a uniform suspension. 
(iii) 20,u1(0.02ml) from each well showing no visible growth was removed and plated out onto 
duplicate blood agar plates. 
(iv) Sample was placed over the entire plate surface with a bent (hockey-stick) glass rod. 
Incubation 
(i) Plates were inverted and incubated 35-3rC for 24 hours. 
Interpretation of results 
(i) Each subculture plate was examined and the number of colonies recorded. 
The mean of both the plates were taken as the final count. 
(ii) The MBC is defined as the lowest concentration of the antimicrobial agent showing 299.9% 
killing. 
(iii) From the initial MIC inoculum the number of colonies allowable for a 99.9% MBC end point 
was calculated. 
(iv) MBC was calculated as follows : 
Initial inoculum x aliquot plated x allowable viable percent 
5x105(CFUs/ml) x 0.02(ml) x 0.001% 
= lOCFUs 
A plate showing > 1 0 CFU s did not meet the 99.9% endpoint. 
s; 10 colonies indicated a ;;. 99.9% killing. 
SECTION F : BREAKPOINT SUSCEPTffiILITY TESTING 
The following concentrations for antibiotics to be tested were chosen according to 
NCCLS Document M7 -A2· 
Penicillin 
Ampicillin 
: 16,ug/ml and 256,ug/ml 
: 8,uglml and 256,uglml 
Imipenem : 4,ug/ml 
Piperacillin : 4,ug/ml 
Ciprofloxacin : 1 and 8,ug/ml 
Vancomycin : 4,uglml 
Teicoplanin : 4,uglml 
Media 
Gentamicin : 8,uglml 
Amikacin : 32,uglml 
Streptomycin: 32,ug/ml 
Cephalothin : 16,uglml 
Cefuroxime : 16,ug/ml 
Cefamandole : 16,ug/ml 
Cefotaxime : 32,uglml 
Mueller-Hinton agar supplemented with 5% lysed horse blood. 
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In addition, Mueller-Hinton only was used to test the aminogylcosides and the cephalosporins. 
Procedure 
(i) Agar plates were prepared with the appropriate antibiotic at the chosen concentrations (either 1 
or 2 plates). 
(ii) Reference strains E.coli ATCC 25922 and S.aureus ATCC 29213 were included with each 
batch of tests and compared to a NCCLS control range. 
(iii) Inoculated pure cultures of test and control organisms into Mueller -Hint on broth and 
incubated at 35-3rC for 2-5 hours until faintly turbid. 
Cultures were adjusted to match a 0.5 McFarland standard that would contain (approximately 
108CFU/ml) using sterile broth. 
Inoculum was further diluted 1: 10 to achieve a final inoculum of approximately 107CFU/ml. 
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The multipoint inoculum replicator apparatus deposits 1 to 2jLI on the agar surface, thus the final 
inoculum on the agar was approximately 104CFUs per spot. 
(iv) After drying the surface of agar plates to be inoculated, 1 to 2jLI of each culture was 
inoculated on the appropriate plates by means of the multipoint inoculator, delivering 37 spots per 
plate including 2 control strains and a marker. 
(v) An antibiotic free control plate was included with each set of inocula. 
(vi) Inoculated plates were allowed to stand at room temperature until the moisture in the 
inoculum spots were dry. 
(vii) Incubated plates at 35-37°C in an atmosphere of5-10% CO2 for 18-24 hours. 
(viii) Results were recorded as growth or no growth for each inoculum spot. 
Interpretation 
No growth at either concentration is interpreted as susceptible. 
Growth at both concentrations indicates resistance. 
Growth only at the lower concentration is interpreted as intermediate. 
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SECTION G: DETECTION OF HIGH-LEVEL AMINOGLYCOSIDE RESISTANCE 
(HLAR) 
Screening method 
Agar screen technique 
Concentration of aminoglycosides used: 
Gentamicin : 500 and 2000Ilg/ml 
Streptomycin : 2000llg/ml 
Media 
Brain-heart infusion agar incorporated with the appropriate amino glycoside at the concentration 
stated above. 
Preparation of inoculum 
(i) Inoculum was prepared by touching 4 to 5 colonies of similar morphology from an overnight 
incubated culture plate and suspended in 0.85% normal saline. 
(ii) The inoculum was standardized to match the turbidity ofa 0.5 McFarland standard 
(approximately 108CFU/ml). 
Inoculation of agar plates 
(i) Plate supplemented with the aminoglycoside was divided into 4 quadrants. 
(ii) Inoculated each quadrant with 10111 of the standardized suspension of I08CFU/ml to achieve a 
final inoculum of I 06CFU s. 
(iii) Inoculated plates were allowed to stand undisturbed at room temperature until the inoculum 
was absorbed into the agar before plates were inverted. 
Incubation 
Medium incubated at 35-37°C in an ambient atmosphere for 18-24 hours; incubation was 
prolonged for a further 24 hours on the plates showing no growth. 
Results 
Plates examined for the presence of bacterial growth (any growth was considered significant). 
(If bacterial growth was evident, the relevant amount ie. light to heavy was noted). 
Quality control 
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Positive growth control : Media lacking an amino glycoside supplement (ie. brain-heart infusion 
agar only) was inoculated for each test organism. 
Gentamicin and streptomycin agar plate controls (2000ug/ml) 
Positive conlrol : Ejaecalis Q.c. 2423 (MIC: 2048jig/ml) 
Negative control : Lab control strain of Ejaecalis (MIC : 1024jig/ml) 
Gentamicin agar plate control (500ug/ml) 
Positive control: Lab control strain E. faecalis (MIC :512jiglml) 
Negative control : Lab control strain E.faecalis (MIC: 128jiglml) 
Interpretation of results 
Results were interpreted as follows : 
No growth in the presence of 500 and 2000jig/ml of gentamicin indicates the absence of high-
level resistance to gentamicin. 
No growth in the presence of2000jiglml of streptomycin indicates the absence of high-level 
resistance to streptomycin. 
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Growth in the presence of 500 and 2000jlg/ml of gentamicin indicates the presence of high-level 
gentamicin resistance. 
Growth in the presence of 500 (not 2000jlg/ml) of gentamicin indicates the presence of high-level 
gentamicin resistance. 
Growth in the presence of streptomycin indicates high-level streptomycin resistance. 
SECTION H: THE STUDY OF SYNERGISM USING TIME-KILL CURVES 
Concentration of antibiotics used: 
Killing curves were performed using the following antibiotics at the stated concentrations. 
Gentamicin : 5,ug/ml (Fixed) 
Vancomycin : 10,ug/ml (Fixed) 




6,ug/ml (MIC < 32,ug/ml) 
50,ug/ml (MIC 32-128,ug/ml) 
100,ug/ml (MIC ~ 256,ug/ml) 
10,ug/ml (MIC < 32,ug/ml) 
50,ug/ml (MIC 32-128,ug/ml) 
100,ug/ml (MIC ~ 256,ug/ml) 
10,ug/ml (MIC < 32,ug/ml) 
50,ug/ml (MIC 32-128,ug/ml) 
100,ug/ml (MIC ~ 256,ug/ml) 
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Drug concentrations selected for testing was based on clinically achievable levels in blood. Each 
of the antibiotics were tested alone and in different combinations. 
Example: Ampicillin tested alone 
Ampicillin plus gentamicin (Gentamicin MIC < 500,ug/ml) 
Vancomycin and penicillin tested individually 
Penicillin plus vancomycin 
Procedure 
(i) Test organisms were grown in brain-heart infusion (BID) broth . 
(ii) Inoculated broth was incubated at 3S-37°C overnight. 
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(iii) Adjusted turbidity of overnight broth by adding fresh sterile broth to match a O.S McFarland 
standard (approximately 108 CFU/ml). 
(iv) From the adjusted inoculum (108 CFU Iml), 0.1 ml was removed and added to O. 9ml of fresh 
brain-heart infusion broth. 
(This gave a final inoculum of 107CFU/ml). 
N .B. (i) Prior to inoculation, each tube of fresh BID broth was supplemented with the 
appropriate aminoglycoside, beta-Iactam or glycopeptide antibiotic either alone or in combination. 
Calculation of concentration required : S ,ug/ml of gentamicin 
A stock solution of gentamicin containing SOO,ug/ml was made. 
O. l ml of gentamicin stock of SOO,ug/ml plus 9.9mls broth containing 107CFU/ml of organisms was 
added. 
This gave a final concentration of S ,ug/ml of gentamicin. 
Positive growth control 
(i) A BID broth tube with only test organisms 107CFU/ml (no antibiotic) was set up as a growth 
control. 
(ii) Inoculated broths were incubated at 3S-37°C aerobically. 
(iii) At 0, 4, 24 hour intervals after inoculation O. l ml portion was removed from the BID broth 
tube and diluted (ie. a serial dilution bacterial colony count perfomed).0.9ml distilled water was 
added to tubes 1 to 8. 0.1 ml of inoculum 107 CFU Iml was added to tube 1. 
Transferred O.lml of diluent from tube 1 to tube 2, O.lml from tube 2 to 3, continued double 
diluting until the last tube. 
The last O.lml was discarded. 
(iv) O. hnl of diluent from each tube was plated out onto duplicate blood agar plates. 
(v) In the same fashion, 0.1m1 of inoculum was removed, after 4 and 24 hours of incubation, 
diluted and 0.1m1 of diluent was plated out onto 2 purity plates. 
Colony counts were performed. 
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(vi) By u,sing the viable colony count determined at each time interval , a 24 hour time kill curve 
was established for each isolate tested. 
Interpretation 
Susceptibility to an aminoglycoside, beta-Iactam or glycopeptide synergy is defined as a > 1 00 fold 
increase in killing by the drug combination over the killing accompanied by the most active of the 
two drugs when tested separately. 
Resistance to synergy is a <100 fold increase in killing. 
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Time-kill study graph data for E. faecalis 
Table XXXII(A) Refer to Fig. 10.1 
TIME-KILL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONe. (CFU/ml) (CFU/ml) (CFU/ml) 
Control 1.5X106 1.8X108 5.8X108 
Genta 32.0 LLR 64.0 5 1.5X106 9.0X107 4.6X108 
Ampi 0.5 S 1.0 10 1.5X106 3.8XlOs 1.8X102 
Pen 1.0 S 64.0 6 1.5X106 2.0XlOs 1.0X102 
Ampi + Genta 1.5X106 7.0X101 1. OX 10° 
Pen + Genta 1.5X106 5.0X101 1.0XlO° 
LLR : Low-level resistance 
HLR : High-level resistance 
MIC : Minimum inhibitory concentration 
MBC : Minimum bactericidal concentration 
S : Susceptible 
R : Resistant 
MIC INT : Minimum inhibitory concentration interpretation 
CFU/ml : Colony forming units per millilitre 
ANTIB. CONC : Antibiotic concentration Cug/ml) 
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Table XXXII(B) Refer to Fig. 10.2 
TIME-IqLL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONe. (CFU/ml) (CFU/ml) (CFU/ml) 
Control 1.5X106 1.8X108 5.8X18 
Genta 32.0 LLR 32.0 5 1.5X106 9. OX 107 4.6X108 
Imipen 1.0 S >64 10 1.5X106 1.5X105 1. OX 102 
Imipen + Genta 1.5X106 3.0XlOl 1. OX 10° 
Table XXXII(C) Refer to Fig. 10.3 
TIME-KILL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONC. (CFU/ml) (CFU/ml) (CFU/ml) 
Control 1.5X106 1.8X108 5.8X108 
Genta 32.0 LLR 64.0 5 1.5X106 9.0X107 4.6X108 
Vanco 1.0 S 16.0 10 1.5X106 9.0X105 1.0X104 
Teico 0.25 S 4.0 5 1.5X106 7.0X105 8AX103 
Vanco + Genta 1.5X106 2.0X102 1. OX 10° 
Teico + Genta 1.5X106 1. OX 102 1. OX 10° 
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Table XXXIII(A) Refer to Fig. 11.1 
TIME-KILL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONe. (CFU/ml) (CFU/ml) (CFU/ml) 
Control 1.8X106 1.4X108 6.4X108 
Genta 32.0 LLR 64.0 5 1.8X106 9.8X107 4.0X108 
Ampi 0.5 S 2.0 10 1.8X106 8.0X104 1.5X102 
Pen 1.0 S 64.0 6 1.8X106 4.0X104 1.0X102 
Ampi + Genta 1.8X106 4.0X102 1. OX 10° 
Pen + Genta 1.8X106 3.0X102 1. OX 10° 
Table XXXIII(B) Refer to Fig. 11.2 
TIME-KILL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONC. (CFU/ml) (CFU/ml) (CFU/ml) 
Control 18X106 1.4X108 6.4X108 
Genta 32.0 LLR 64.0 5 1.8X106 98X108 4.0X108 
Imipen 0.25 S >64 10 1.8X106 2.1X104 2.0X102 
Imipen + 1.8X106 2.2XI02 1. OX 10° 
Genta 
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Table xxxrrI(C) Refer to Fig. 11 .3 
I 
TIME-KILL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONe. (CPU/m!) (CFU/m!) (CPU/m!) 
Control 1.8X106 1.4X108 6.4X108 
Genta 32.0 LLR 64.0 5 1.8X106 9.8X107 4.0X108 
Vanco 1.0 S 16.0 10 1.8X106 2.8X105 2.0X104 
Teico 0.5 S 4 .0 5 1.8X106 2.0X105 1.2X104 
Vanco + Genta 1.8X106 2.2X103 1. OX 10° 
Teico + Genta 1.8X106 1. 4X 103 1. OX 10° 
Table XXXIV(A) Refer to Fig. 12.1 
TIME-KILL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONe. (CFU/m!) (CFU/m!) (CFU/m!) 
Control 2.5X106 1.6X108 8.0X108 
Genta ~2000 HLR 
Ampi 0.5 S 1 .0 10 2.5X106 6 .0X105 1. OX 103 
Vanco 1.0 S 16.0 10 2.5X106 1. 6X 105 5.5X103 
Teico 0.25 S 4.0 5 2.5X106 8.8X104 4.0X103 
Ampi + Vanco 2.5X106 4.3X104 1.0XlO° 
Teico + Vanco 2.5X106 2 .5X104 1. OX 10° 
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Table XXXIV(B) Refer to Fig. 12.2 
TIME-KILL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONe. (CFU/ml) (CFU/ml) (CFU/ml) 
Control 2.5X106 1.6X108 8.0X108 
Genta ;;..2000 HLR 
Pen 0.5 S 64.0 6 2 .5X106 4.8X105 1. OX 103 
Vanco 1.0 S 16.0 10 2.5X106 1.6X105 5.0X103 
Teico 0.25 S 4.0 5 2.5X106 8.4X104 4.lX103 
Pen + Vanco 2.5XI06 6. OX 104 1. OX 10° 
Pen + Teico 2.5X106 3.0X104 1. OX 10° 
, 
Table XXXVIC Refer to Fig. 12.3 
TIME-KILL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONe. (CFU/ml) (CFU/ml) (CFU/ml) 
Control 2.5X106 1.6X108 8.0X108 
Genta ;;.. 2000 HLR 
Imipen 0.5 S >64 10 2.5XI06 3.8X105 7.0X102 
Vanco 1.0 S 16.0 10 2.5XI06 1.6X105 5.5XI03 
Teico 0.25 S 4.0 5 2.5X106 8.8X104 4.0X103 
Imipen + Vanco 2.5X106 5.0XI04 1. OX 10° 
Imipen + Teico 2.5XI06 3.0X104 1. OX 10° 
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Table XXXV(A) Refer to Fig. 13.1 
TIME-KILL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONC. (CFU/ml) (CFU/ml) (CFU/ml) 
Control l.6X10
6 4.0X108 7.7X108 
Genta ;;.2000 HLR 
Ampi 0.5 S l.0 10 l.6X10
6 3.0X105 1.0X102 
Vanco 1.0 S 32.0 10 1.6XI0
6 6.0X105 2.2X103 
Teico 0.5 S 4.0 5 1.6X10
6 4.5X105 l.6X103 
Ampi + Vanco 1.6XI0
6 l.8X104 1. OX 10° 
Ampi + Teico 1.6XI0
6 9.4X103 1. OX 10° 
Table XXXV(B) Refer to Fig. 13 .2 
TIME-KILL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONe. (CFU/ml) (CFU/ml) (CFU/ml) 
Control 1.6X106 4. OX 108 7.7X108 
Genta ;;.2000 HLR 
Pen 0.5 S 32.0 6 1.6XI06 2.6X105 1.0XI02 
Vanco 1.0 S 32.0 10 l.6X106 6,OXI05 2.5XI03 
Teico 0.5 S 4.0 5 1.6X106 4.8X105 1.0XI03 
Ampi + Genta 1.6XI06 2.2X104 1. OX 10° 
Pen + Genta 1.6X106 1.0XI04 1. OX 10° 
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Table XXXV(C) Refer to Fig 13.3 
TIME-KILL STUDY 
ANTIBIOTIC MIC MIC .MBC ANTIB . OHRS 4 HRS. 24HRS 
INT. CONe. (CFU/ml) (CFU/ml) (CFU/ml) 
Control 1. 6X 106 4.0X108 7.7XI08 
Genta ~2000 
Imipen 0.25 S >64 10 1.6X106 3.0X105 1.5X102 
Vanco 1.0 S 32.0 10 1.6X106 6.5X105 2.4X103 
Teico 0.5 S 4.0 5 1.6X106 4.5X105 2.0XI03 
Imipen + Vanco 1.6X106 2.9X104 1. OX 10° 
Imipen + Teico 1.6X106 2.0X104 1. OX 10° 
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Time kill study graph data for E. faecium 
Table XXXVI(A) Refer to Fig. 14.1 
TIME-Kll.L STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONC. (CFU/mI) (CFU/mI) (CFU/mI) 
Control 9.9X105 1.2X108 6.8X108 
Genta 1024 LLR ~ 2000 S 9.9X105 7.5X107 3.SX108 
Ampi 32.0 R >256 SO 9.9X105 3.2X105 1.3X104 
Pen 128 R >2S6 9.9X105 4.6X105 3.6X104 
Ampi + Genta 9.9X105 3.0X104 9.0X103 
Pen + Genta 9.9X105 6.2XI04 2.SX104 
Table XXXVI(B) Refer to Fig. 14.2 
TIME-KILL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONC. (CFU/mI) (CFU/mI) (CFU/mI) 
Control 9.9X105 1.2X108 6.8X108 
Genta 1024 LLR ~2000 5 9.9X105 7.SX107 3.SX108 
Imipen 128 R >256 SO 9.9X105 2.0XI05 3.0X104 
Imipen + Genta 9.9X105 1.3X105 2.2X104 
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Table XXXVIC Refer to Fig. 14.3 
TIME-KILL STUDY 
ANTIBIOTIC :MIC :MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONC. (CFU/ml) (CFU/ml) (CFU/ml) 
Control 9.9X105 1.2X10
8 6.8X108 
Genta 1024 LLR z2000 5 9.9X105 7.5X10
7 3.5Xl08 
v'anco 1.0 S 32.0 10 9.9X105 6.5X105 3.2X10
4 
Teico 0.25 S 16.0 9.9XlOs 5.3XlOs 2.2X104 
Vanco + Genta 9.9XlOs 3.OXlOs 1.8X104 , 
Teico + Genta 9.9XlOs 2.2XlOs 1. OX 104 
Table XXXVII(A) Refer to Fig. 15 .1 
TIME-KILL STUDY 
ANTIBIOTIC :MIC :MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONe. (CFU/ml) (CFU/ml) (CFU/ml) 
Control 9.9XlOs 1.0X108 6.2X108 
Genta 8.0 LLR 64.0 5 9.9X105 9.8X107 4.8X108 
J 
f\mpi 0.5 S 1.0 10 9.9X105 1.8X105 9.0X103 
Pen 0.5 S 16.0 5 9.9X105 9.9X107 8.2X103 
Ampi + Genta 9.9XlOs 8.5X103 9.8X101 
Pen + Genta 9.9XlOs 7.0X103 9.0X101 
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Table XXXVII(B) Refer to Fig. 15.2 
TIME-KILL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONe. (CFU/ml) (CFU/ml) (CFU/ml) 
Control 9.9X10
5 1. OX 108 6.2Xl08 
Genta 8.0 LLR 64.0 5 9.9X10
5 9.9X107 4.8XI08 
Imipen 0.25 S 32 10 9.9X105 1.0X10
5 6.8X103 
Imipen + Genta 9.9X105 6.6X103 8.7X101 
Table XXXVII(C) Refer to Fig. 15.3 
TIME-KILL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONe. (CFU/ml) (CFU/ml) (CFU/ml) 
Control 9.9X105 1.0X108 6.2X108 
Genta 8.0 LLR 64.0 5 9.9X105 9.8X107 4.8X108 
Vanco 1.0 S 32.0 10 9.9X105 5.1X105 1.8X104 
Teico 0.25 S 16.0 5 9.9X105 4.0X105 8.5X103 
Vanco + Genta 9.9X105 6.5X103 9.5X101 
Teico + Genta 9.9X105 5.8X103 8.8X101 
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Table XXXVIII(A) Refer to Fig. 16.1 
TIl\1E-KILL STUDY 
ANTffiIOTIC MIC MIC MBC ANTffi. OHRS 4 HRS. 24HRS 
INT. CONe. (CFU/mJ) (CFU/ml) (CFU/ml) 
Control 9.5XI05 9.5XI07 6.0X108 
Genta ~2000 HLR 
Ampi 64.0 R >256 50 9.5X105 4.4X105 2.4X105 
Vanco 1.0 S 64.0 10 9.5X105 9. OX 105 7.8XI04 
Teico 0.5 S 32.0 5 9.5X105 6.8X105 7. OX 104 
Ampi + Vanco 9.5X105 3.9XI05 1.7X104 
Ampi + Teico 9.5XlOs 3.0X105 1. OX 104 
Table XXXVIII(B) Refer to Fig. 16.2 
TIl\1E-KILL STUDY 
~NTffiIOTIC MIC MIC MBC ANTffi. OHRS 4 HRS. 24HRS 
INT. CONC. (CFU/ml) (CFU/ml) (CFU/ml) 
Control 9.5X105 9.5XI07 6.0X108 
Genta ~2000 HLR 
Pen 128 R >256 50 9.5X105 2.9X106 8.8X105 
Vanco 1.0 S 64.0 10 9.5X105 9.0X105 7.8XI04 
Teico 0.5 S 32.0 5 9.5X105 7.0X105 7.0XI04 
Pen + Vanco 9.5X105 6.4X105 2.0XI04 
Pen + Teico 9.5X105 4.9XI05 1. OX 104 
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Table XXXVIIIC Refer to Fig. 16.3 
( 
TIME-KllL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONe. (CFU/mJ) (CFU/ml) (CFU/mJ) 
Control 9.5XI05 9.5X107 6.0X108 
Genta L2000 HLR 
Imipen 128 R >256 50 9.5X105 9.2X105 5.0X105 
Vanco 1.0 S 4.0 10 9.5X105 7.0X105 7.8X104 
Teico 0.5 S 9.5X105 4.8X105 4.5X104 
Imipen + Vanco 9.5X105 2.1X104 1.5XI04 
Imipen + T eico 9.5X105 1. OX 105 1. OX 104 
Table XXXIX(A)Refer to Fig. 17.1 
TIME-KILL STUDy 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONe. (C~/mJ) (CFU/mJ) (CFU/mJ) 
Control 9.8XI05 1. OX 108 5.9X108 
Genta L2000 HLR 
Ampi 64.0 R >256 100 9.8X105 8.6X105 6.0X105 
Vanco 1.0 S 32.0 10 9.8X105 5.0X105 3.0X104 
Teico 0.5 S 16.0 5 9.8X105 3.2X105 1.7X104 
Ampi + Vanco 9.8X105 2.2X105 1. OX 104 
Ampi + Teico 9.8X105 9.5XI04 9.0X103 
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Table XXXIX(B)Refer to Fig. 17.2 
, 
TIME-KILL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONe. (CFU/mJ) (CFU/mJ) (CFU/mJ) 
Control 9.8X105 1.0X108 5.9X108 
Genta ~2000 HLR 
Pen 256.0 R >256 100 9.8X105 1.2X107 8.5X106 
Vanco 1.0 S 32.0 10 9.8X105 5.0X105 3.OX104 
Teico 0.5 S 16.0 5 9.8X105 3.2X105 1.8X104 
Pen + Vanco 9.8X105 2.2X105 1.0X104 
Pen + Teico 9.8X105 9.8X104 9.0X103 
Table XXXIX(C) Refer to Fig. 17.3 
TIME-KILL STUDY 
ANTIBIOTIC MIC MIC MBC ANTIB. OHRS 4 HRS. 24HRS 
INT. CONe. (CFU/ml) (CFU/ml) (CFU/mJ) 
Control 9.8X105 1. OX 108 5.9X108 
Genta ~2000 HLR 
Imipen 256.0 R >256 100 9.8X105 8.8X106 6.5X106 
Vanco 1.0 S 32.0 10 9.8X105 5.0X105 3.OX104 
Teico 0.5 S 16.0 5 9.8X105 3.1X105 2.1X104 
Imipen + Vanco 9.8XI05 2.0X105 1.6X104 
Imipen + T eico 9.8X105 1.0X105 9.4XI03 
SECTION le TYPING OF ENTEROCOCCI USING PULSED-FIELD 
GEL ELECTROPHORESIS (PFGE) 
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The procedure used for the pulsed-field gel electrophoresis was according to Murray et al. (79). 
(i) Enterococci were grown overnight in Smls of brain-heart infusion broth at 37 DC overnight. 
(ii) Cells were harvested and suspended in an equal vol ofPVI buffer (lM NaCl, lOmM Tris-HCI) 
[pH 7.6]. 
(iii) A portion (2.Smls) of this suspension was mixed with 2,Smls of 1.6% low melting-
temperature agarose in water at 40-S0DC. 
The agarose was then pipetted into a plug mold to allow to solidify. 
(iv) For lysis, five plugs were placed in 10mls offresh solution (which was made up just before 
use). The lysis solution contained 6mM Tris-HCI (pH 7.6), 1M NaCl, 100mM EDTA (pH 7.S), 
0.5% Brij, 0.2% deoxycholate, 0.5% sodium lauroyl sarcosine, 20,ug RNase (DNase free) per ml 
and 1mg oflysozyme per ml. 
(v) Plugs were incubated overnight at 3S-3rC with gentle shaking. 
This solution was replaced with lOml ESP (Proteinase K SO,ug/ml, 1% Sarkosyl, O.SM EDTA 
(pH 9.0). and then incubated overnight at SODC with gentle shaking. 
(vi) The plugs were washed 3 times for 30minutes each time with lSml TE solution (lOmM Tris-
HCI [pH 7.S], 1rnM EDTA). 
The plugs were stored at 4 DC until their use. 
(vii) Digestion with restriction enzyme Sma I was performed by placing a small slice (about 1-
2mm thick) of an agarose plug in a microfuge tube with 200,ul of distilled water, followed by 2S,u1 
of reaction buffer and 2,u1 of Sma I (Boeringer-Mannheim). 
This was incubated at 2S DC for 12 hours. 
The slices were washed with 1ml ofTE for 1 hour at 3rC. 
They were then melted at 55 to 65 0 C and loaded into wells of 1.2% agarose gels (Sea Plaque 
GTG agarose) in 0.5x TBE buffer (0.089M Tris-HCI, 0.089 boric acid, 0.0025M EDTA). 
Lambda concatemers were used as a size standard. 
Electrophoresis was performed with the Contoured-Clamped Homogeneous Electric Field 
apparatus (CHEF-DRII; Bio-Rad). 
Pulse time was increased from 5 to 35 seconds over 24 hours at 200V for 32 hours. 
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Gels were stained for 30 minutes with ethidium bromide followed by 12 hours of destaining with 
distilled water. 
They were photographed with UV radiation. 
